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Clinical drug research
In clinical research, experiments with human participants are conducted to obtain 
generalizable information that will improve medical knowledge and support 
clinical decision making by doctors. New drug treatments are extensively tested in 
trials with human subjects before they are allowed to enter the market. Also after 
approval by regulatory authorities, clinical drug trials are important to improve our 
knowledge about the safe and effective use of drugs. In addition, drugs are used in 
clinical trials as tools to investigate (patho-)physiology in humans in vivo. Clinical 
research with pharmaceutical agents can be divided into successive phases.
[1] Exploratory clinical development, or early phase research, is preceded by 
preclinical research including studies with animals, cells, and tissues. Exploratory 
clinical development includes trials that are classically categorized as phase I and 
phase II trials.[1] Phase I studies usually have non-therapeutic objectives and may 
be conducted in healthy volunteer subjects or certain types of patients for a first 
impression of the pharmacological characteristics of the drug in humans. Drug 
tolerance, metabolism, and interactions are examined and pharmacokinetics and 
pharmacodynamics are described.[2] Phase II is typically considered to start with 
the initiation of studies in which the primary objective is to explore therapeutic 
efficacy in patients. An important goal for this phase is to determine the dose 
response relationship for the indication in question.[2] Exploratory clinical 
development is followed by confirmatory clinical development, or late phase 
research, including phase III and phase IV trials. Phase III studies are designed to 
confirm the preliminary evidence accumulated in Phase II that a drug is safe and 
effective for use in the intended indication and patient population. These studies 
provide the basis for marketing approval of a drug. After regulatory approval, 
phase IV trials are conducted to examine drugs in broad or special populations 
and to identify uncommon adverse events.[2] However, some trials may not 
fit into a single phase, and may blend from phase I to phase II or from phase II 
to phase III.[1] In addition, also after marketing approval, phase I-III trials can 
still be conducted to explore new indications or to assess pharmacokinetic or 
pharmacodynamic interactions with new compounds.
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Sponsorship of drug trials
Clinical drug trials can be sponsored by pharmaceutical companies, but also 
by non-profit organizations including hospitals, universities, foundations, and 
governmental organizations. Trials funded by non-profit organizations are often 
referred to as non-industry or investigator-initiated studies. There is great diversity 
in the degree to which the funding body can be involved in drug trials, ranging from 
purely financial support or donation of study medication by a pharmaceutical 
company to involvement in the study design, data collection and analysis, decision 
to publish the results, and preparation of the article.[3] In the guidelines for Good 
Clinical Practice (GCP) for drug trials with human subjects from the International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) [4], the sponsor of a study is defined as an 
individual, company, institution, or organization which takes responsibility for the 
initiation, management, and/or financing of a clinical trial. Sponsorship of a trial 
includes numerous responsibilities and obligations. The sponsor is responsible for 
the safety of participating subjects and the quality and integrity of the data that is 
collected. Therefore, the sponsor has to implement and maintain quality systems 
to ensure that trials are conducted and data are generated, documented, and 
reported in compliance with the study protocol, GCP guidelines, and regulatory 
requirements.[4] The sponsor is responsible for the appointment of qualified 
study staff, the selection of research sites, appropriate management of data and 
study documents, participant and liability insurances, and submission of research 
protocols to research ethics committees (RECs) for approval.[4] Furthermore, the 
sponsor has to ensure that sufficient data is available on the safety and efficacy 
of the study drug, that the preparation and packaging of the drug meets all legal 
requirements, and that the drug is correctly delivered to researchers. During the 
trial, the sponsor is responsible for the ongoing evaluation of the safety of the 
experimental drug and for the reporting of adverse events to researchers, RECs, 
and competent authorities.[4] 
Quality of drug trials
Over the last years, the quality and integrity of clinical drug research has frequently 
been criticized. It has been suggested that involvement of the pharmaceutical 
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industry adversely affects the quality of clinical trials, which could lead to 
distorted information on the efficacy and safety of drug treatments that can be 
misleading for doctors and patients.[5-8] In studies that investigated whether 
disclosure of funding sources or financial conflicts of interest among authors 
influenced readers’ interpretations of published research, conflicting results were 
found. Some studies showed that declaration of competing interests or industry 
sponsorship negatively affected the perception of the credibility and quality of 
trials [9-11], and reduced the willingness of physicians to act on trial findings.[11] 
However, other studies found no evidence of a large impact of mentioning funding 
sources or conflicts of interest on the confidence in the conclusions of trials or the 
likelihood of prescribing the drug by physicians.[12, 13] 
Every clinical drug trial consist of a series of consecutive steps, including the design 
of the study, the actual conduct, and the publication of results (Figure 1). With 
regard to the quality of a trial, a distinction can be made between internal and 
external validity. Internal validity, or methodological quality, is determined by the 
extent to which observed treatment effects in a trial can be ascribed to differences 
in treatment and not bias, so a causal association can be inferred between the 
treatment and outcomes.[14] External validity is the extent to which the study 
results can be generalized to the population that the study participants were 
meant to represent.[14] Internal validity is a prerequisite for external validity, as 
the study results will not have any implications for clinical practice if the trial is of 
insufficient methodological quality. However, internal validity does not inherently 
lead to external validity, as there may be factors in the general patient population 
that differ from the study population and influence the treatment effect found in 
the trial.[15] Therefore, the quality of a clinical trial can be affected during each 
successive step of a study.
Trial design
Through the design of a trial, the results can be influenced to the advantage of 
the study sponsor or investigator. Several ways have been described in which the 
chance of detecting superiority for the experimental drug can be increased by 
design adjustments.[16-18] It is possible to make a new drug look favorable by 
comparing it to placebo instead of to a treatment already proven to be effective. 
However, when a specific class of drugs is known to be effective and a (new) drug 
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from that class is compared to placebo instead of existing treatments, there is 
no fair comparison. A comparison between two active treatments will be more 
likely to be favorable for the experimental drug when an inadequate dose of the 
comparator drug is used. In addition, trial results can be influenced by using a 
highly selected patient population for which success is likely, selection of specific 
(surrogate) outcome measures and statistical analyses, or selection of a study 
duration during which it is unlikely that adverse events will occur with the new 
drug. However, these choices affect the clinical relevance of study results and the 
applicability of the trial to the population that will actually take the drug, that is, 
the external validity of the trial. The concept of equipoise, the uncertainty principle, 
plays a central role in the design of a trial. Equipoise means that when different 
treatments are compared, there needs to be a reasonable amount of uncertainty 
about the treatment that will be preferred when the risks and therapeutic benefits 
of each study arm are weighed.[19] Large deviations from equipoise can occur 
through design bias, as described above. However, the uncertainty principle may 
not be exclusively valid with an a priori probability of 50/50.[20] Investigators can 
be unsure whether a new drug is better than the comparator treatment, even if 
the chance of superiority is larger than 50% because the drug has been selected at 
earlier stages based on preclinical and early clinical studies suggesting advantages 
over existing treatments.[20-22] 
Over the last decades, it has repeatedly been shown that studies that are 
sponsored by pharmaceutical companies are more likely to have outcomes that 
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are favorable to the sponsor than studies with other funding sources.[23-28] It has 
been suggested that this bias in industry-sponsored research may partly result 
from violations of the uncertainty principle.[24, 25, 27] Few studies have directly 
examined the association between industry sponsorship and the design of trials. 
Some studies have shown that industry-sponsored trials more often use placebos 
or no treatment as control groups than non-industry trials [24, 29-31]. In contrast, 
another study found that differences in study protocol, including the use of placebo 
controls and active comparators, could not be attributed to the type of funding 
[32]. This was confirmed in a recent study that showed that trials having industry 
funding with industry collaboration in the design, analysis, or reporting were not 
more likely to use placebo comparators than non-industry trials. However, industry 
trials were more likely to use surrogate primary endpoints.[33] Furthermore, one 
study indicated that industry-sponsored trials were more likely to use active 
comparators and non-profit trials were more often placebo controlled trials.[23] 
Apart from the comparator used, in- and exclusion criteria can affect the pre-test 
likelihood of the trial to have positive results. An analysis of the external validity of 
large industry-sponsored COPD studies in relation to primary care COPD patients 
showed that there were clear differences between trial participants and primary 
care patients. The majority of these patients would not be eligible for inclusion in 
these trials, although most COPD patients are treated in primary care.[34] 
Trial conduct
During the actual conduct of a clinical trial, the risk of systematic bias should be 
minimized and the study should be carried out as described in the predefined 
protocol. Several tools have been developed to assess the methodological 
quality, or internal validity, of clinical trials.[35] An often used tool is the Jadad 
scale.[36] This scale consists of three questions, including whether the trial is 
described as randomized, whether it is described as double-blind, and whether 
there is a description of withdrawals and drop-outs. Additional points are given 
if the method to generate the sequence of randomization was described and was 
appropriate (table of random numbers or computer generated) and if the method 
of double blinding was described and was appropriate (identical placebo or 
dummy). The Cochrane collaboration advises researchers to use its ‘Risk of bias’ 
assessment tool.[37] This tool evaluates seven items, including random sequence 
generation, allocation concealment, blinding of participants and personnel, 
14
Chapter 1
blinding of outcome assessors, incomplete outcome data, selective outcome 
reporting, and other sources of bias. Each item should be judged as low risk, high 
risk, or unclear risk of bias. A difficulty in assessing the methodological quality of 
published trials is the obstacle provided by incomplete reporting. Although the 
emphasis should be on the risk of bias in the conduct of the study, this can be 
confused with assessment of the adequacy of reporting.[37, 38] 
Previous studies have found that the methodological quality of trials financed 
by pharmaceutical companies was not any worse than that of trials financed 
in other ways.[26, 27, 39, 40] Some studies showed that industry trials tended 
to have higher methodological scores than non-industry trials.[24, 25, 41-43] 
In these studies, the Jadad scale and other quality scales were used to assess 
the risk of bias in trials. Based on these studies, it seems that the finding that 
sponsorship by the manufacturing company leads to more favorable results than 
sponsorship by other sources cannot be explained by the use of methods that 
increase the risk of bias.[26, 27] In addition to taking measures that minimize the 
risk of systematic bias, trials should be conducted and completed as planned 
in the protocol to guarantee internal validity. However, it has been shown that 
premature discontinuation of trials is common.[44-47] A frequently reported 
reason for discontinuation is poor recruitment of participants.[44] Non-industry 
trials seem to have more problems in recruiting the required number of subjects 
than studies initiated by pharmaceutical companies.[44, 45, 48] 
Reporting of results
When a clinical trial is completed and participants are no longer being examined 
or treated, the final step of a study includes the interpretation of data and 
publication of results in the scientific literature. However, it has been shown that 
a considerable proportion of trial results are not published in peer-reviewed 
medical journals after study completion.[49-54] The low rate of trials that are 
timely published is a major issue, and does not seem to be unique to industry-
sponsored trials.[55] A study with trials funded by the National Institutes of Health 
(NIH, US governmental organization) found that fewer than half of the trials were 
published in a biomedical journal within 30 months of trial completion. After a 
median of 51 months after completion, a third of trials remained unpublished.
[51] Another study showed that the publication rate within 24 months of trial 
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completion was lower for industry-funded trials (32%) than government-funded 
trials (53%). However, after at least 3 years between trial completion and the 
search for publication of results, the overall publication rate tended to be higher 
for industry-funded trials (66%) than for government-funded trials (55%).[23] A 
recent study that investigated timely disclosure of results of company-sponsored 
trials related to new medicines approved by the European Medicines Agency 
(EMA) showed that results of over three-quarters of the trials were disclosed in 
the scientific literature or in clinical trial registries within a year of completion or 
regulatory approval.[56] 
In addition to non-publication of trials, it has been found that trials are published 
with other (primary) outcomes than originally described in protocols or trial 
registries.[57-62] There is strong evidence of an association between results 
that are in favor of an intervention and publication in the scientific literature. 
Studies reporting positive results are more likely to be published and outcomes 
that are statistically significant have higher odds of being fully reported.[58, 63-
66] As a consequence of this selective publication, published articles as well 
as systematic reviews and guidelines that incorporate them overestimate the 
benefits of interventions and underestimate their harmful effects.[65] Because of 
this, patients may be put at risk and healthcare resources are wasted. In addition, 
withholding of trial results matters because study participants assume that they 
are contributing to the advancement of medical knowledge. Non-publication of 
results negates this assumption and betrays those who volunteered.[67] When the 
dissemination of study results is influenced by the nature and direction of results, 
reporting bias arises.[68] Besides a higher chance of publication, positive results 
are more likely to be published rapidly, more likely to be published more than 
once, more likely to be published in high impact journals, and more likely to be 
cited by others.[68] Publication bias refers to publication or non-publication of 
entire studies depending on the nature and direction of results, while outcome 
reporting bias occurs when some outcomes but not others are selectively reported 
depending on the nature and direction of results.[68] 
As stated previously, it has been shown that industry-sponsored trials are more 
likely to report positive results than those funded by other sources.[24-26, 69-
71] Financial conflicts of interest among authors of published articles have also 
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been associated with favorable results and conclusions.[72-75] Publication bias 
and outcome reporting bias are often mentioned as explanations for this bias 
that favors products that are made by the pharmaceutical company funding 
the research.[24, 25] In addition to the withholding of trial results, authors may 
consciously or subconsciously shape the impression of their results in published 
articles, that is, to add ‘spin’ to study reports. Spin includes the use of specific 
reporting strategies to highlight that the experimental treatment is effective, 
despite statistically non-significant results for the primary outcome, or to distract 
readers from non-significant results. This distorts the interpretation of trial results 
and misleads readers.[76] Different studies have shown evidence of inconsistencies 
between the results and the interpretation of findings in published articles.[76-78] 
Initiatives to improve the quality of clinical trials
Over the last years, different initiatives have been proposed to improve the quality 
of clinical trials. Due to the worldwide call for transparency in the trial process and 
to address selective publication, more strict guidelines and legislation have been 
developed and implemented. 
CONSORT statement
To be able to understand the conduct of a trial and assess the validity of its 
results, readers of published articles need complete and clear information on 
the methodology and results of trials. However, many trial reports fail to provide 
transparent and complete descriptions of essential information.[79, 80] This lack 
of adequate reporting led to the development of the CONSORT (Consolidated 
Standards of Reporting Trials) statement by researchers and journal editors.
[81] The CONSORT statement includes a 25 item checklist and a flow diagram 
and provides guidance for the reporting of randomized controlled trials (RCTs), 
focusing on the most common design type – individually randomized, two group, 
parallel trials. The checklist consists of items related to the content of the title, 
abstract, introduction, methods, results, discussion, and other information 
including trial registration and funding. The flow diagram depicts the progress of 
participants through the stages of a trial, that is, enrolment, intervention allocation, 
follow-up, and data analysis. Adherence by authors and journals to CONSORT 
facilitates clarity, completeness, and transparency of reporting.[81] Today, the 
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CONSORT statement is explicitly supported by more than 400 medical journals 
published around the world.[81] It has been shown that after the publication and 
implementation of CONSORT, the reporting of several important aspects of trial 
methods improved in published trial reports [82-85], although the overall quality 
of reporting still remained below an optimal level.[83]
Registration of clinical trials 
Already since the 1980s, researchers, medical journals, and patient advocacy 
groups called for the creation of publicly accessible registries of clinical trials.
[86, 87] Trial registration involves submitting important information about the 
condition under study, the interventions tested, recruitment criteria, and location 
of trial sites into registries. The original purpose of registration was to facilitate 
access to information on all trials, whether published or not, to investigators and 
systematic reviewers. Trials that were not published could then be identified, the 
trial investigators contacted, and the available trial evidence for an intervention 
could be assessed. This would help to eliminate publication bias.[88] In 1997, the 
US Food and Drug Administration Modernization Act (FDAMA) [89] established 
a US-based trial registry, ClinicalTrials.gov. In 2000, ClinicalTrials.gov was made 
publicly accessible and in addition, several other registries were established. 
However, the mandated content to be posted was narrowly defined by law, and 
investigators, whether funded by commercial sponsors, government agencies, or 
academic institutions, largely ignored the requirement to register.[88] In 2004, the 
International Committee of Medical Journal Editors (ICMJE) announced that their 
journals, which includes those that are regarded as the most prestigious journals, 
would not publish reports of trials unless they had been registered at initiation.
[90] This decision was an important motivator for both pharmaceutical companies 
and academia to register their trials [91], as there are substantial benefits for 
sponsors and investigators from having their results published in high-impact 
journals. The World Health Organization (WHO) also declared support for trial 
registration and launched the WHO International Clinical Trials Registry Platform 
(ICTRP) in 2006 [92], a portal through which major trial registries can be accessed, 
including ClinicalTrials.gov, the International Standard Randomized Controlled 
Trial Number (ISRCTN) Register, the Australian New Zealand Clinical Trials Registry 
(ANZCTR), and the Netherlands Trial Register (NTR). 
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In 2007, the US Food and Drug Administration Amendments Act (FDAAA) was 
signed into law [93], which made the requirements for registration more explicit 
than they had been previously. The FDAAA requires registration of all applicable 
trials that are subject to Food and Drug Administration (FDA) regulation. Generally, 
this includes trials of drugs, devices, or biologicals, which have at least one trial 
site in the United States, and are of phase II or later. The requirements apply to all 
investigators and sponsors, regardless of their source of funding. In addition, the 
FDAAA mandates that basic summary results from registered trials of approved 
products are submitted to ClinicalTrials.gov generally within 1 year of the 
completion of collection of primary outcome data.[93] ClinicalTrials.gov is now 
the world’s largest repository of trial information, containing more than 179,000 
studies conducted in 187 countries. In Europe, the EMA established a legally 
mandatory registry in 2004 for drug trials that are subject to EMA regulation, the 
European Union drug regulating authorities clinical trials (EudraCT) database.[94] 
Initially, information in EudraCT was not publicly accessible, but the EMA launched 
the EU Clinical Trials Register (EU-CTR) in 2011 to provide the public with protocol-
related information held in EudraCT. The EU clinical trials regulation that will be 
implemented in 2016 will require that for all registered trials, a detailed summary 
of results and a lay summary is published on the register within one year from trial 
completion.[95] 
Other organizations that support trial registration include the World Medical 
Association (WMA). In 2008, the WMA added an item to the Declaration of Helsinki, 
stating that every clinical trial must be registered in a publicly accessible database 
before recruitment of the first subject.[96] The Health Research Authority (HRA), 
which is responsible for the national oversight of RECs in the UK, has made 
prospective registration a requirement for ethical approval of any trial conducted 
in the UK since 2013.[97] In parallel with these developments, pharmaceutical 
companies made joint commitments to improve transparency of clinical trials. 
In 2005, the International Federation of Pharmaceutical Manufacturers and 
Associations (IFPMA), representing the global pharmaceutical industry, prepared 
a Joint Position paper [98] which called for routine disclosure of trial information 
including results through registries and databases, which was updated in 2009.
[99] Pharmaceutical companies represented by the European Federation 
of Pharmaceutical Industries and Associations (EFPIA), the Pharmaceutical 
19
General introduction 1
Research and Manufacturers of America (PhRMA), and the Japan Pharmaceutical 
Manufacturers Association (JPMA) signed up to these principles. In addition, 
a similar industry Joint Position paper was announced in 2010 to cover the 
publication of trial results in the scientific literature.[100] In this document, it is 
stated that all industry-sponsored trials should be considered for publication in 
peer-reviewed journals irrespective of whether results are positive or negative. At a 
minimum, results from all phase III trials and any trial results of significant medical 
importance should be submitted for publication, including investigational 
products whose development programs are discontinued.[100]
Current use of trial registries
Despite the developments described above, research on the registration status 
of published trials has shown that around 30% to 40% of clinical trials were not 
registered.[57, 101-103] Other studies showed that among registered trials, a 
significant proportion remained unpublished after trial completion.[23, 49, 51, 
101, 104] Furthermore, it was found that many trials were inadequately registered, 
lacking essential information on protocol elements including primary and 
secondary outcomes, details of interventions, sample size, randomization, and 
blinding.[62, 105-108] One study showed that government-funded trials were more 
likely to be missing data about study design and intervention arms than industry-
sponsored trials, although for all types of trials ambiguous and contradictory 
data entries were observed.[105] Poor quality of information in registries can 
undermine the benefits of trial registration, including the improved transparency 
on trials for healthcare workers and patients, increased accountability of trialists, 
and the potential to address selective reporting.[107] In addition, although the 
ICMJE requires that trials are prospectively registered, that is, before participant 
enrolment, it has been found that many trials were retrospectively registered.[107-
109] Trial registration before the start of a study is important so that registration 
is not influenced by the results. While the posting of basic results in ClinicalTrials.
gov after completion is now a legal requirement for trials that are covered by the 
FDAAA [93], it has been found that many trials that are subject to this mandatory 
reporting did not post results within one year of completion.[109-113] A recent 
study showed that only 22% of clinical trials subject to FDAAA requirements 
had results posted on ClinicalTrials.gov within the legally required 12-month 
timeframe.[110] Industry-sponsored trials were more likely to post results (40%) 
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than those sponsored by governmental or academic institutions (9%).[110] Other 
studies confirmed that trials with industry funding were more compliant with the 
FDAAA regarding results reporting than those with academic funding.[111-114]
Other initiatives for transparency in clinical research
In 2013, the AllTrials campaign was launched by the charity Sense About Science, 
the British Medical Journal (BMJ), and other supporters of transparency in research.
[115] AllTrials calls for all past and present trials to be registered and their results 
reported. Four levels of information are mentioned: 1) knowledge that trials are 
conducted, from trial registries; 2) a summary of trial results; 3) full details about 
the methods and trial results; and 4) individual patient data from the trial.[116] 
The AllTrials campaign is concerned with the first three levels of information. First, 
planned trials should be prospectively registered and past trials that were not 
registered should be registered retrospectively now. Second, a summary of results 
should be publicly available in trial registries within one year of study completion. 
Summary results from past trials of drugs that are currently in use should be posted 
on a registry now. Third, sponsors and others who produce full reports (clinical 
study reports (CSRs), or their equivalent in non-commercial studies) should make 
these publicly available. CSRs are formal reports providing more details on the 
methods, analysis, and study results than published articles and form the basis 
of submissions to drug regulators, when pharmaceutical companies seek to have 
their drugs approved. AllTrials suggests that individual patient data in CSRs can be 
redacted and made available on request to researchers.[116] The AllTrials petition 
has now been signed by more than 80,000 people worldwide and by more than 
500 organizations. 
Some pharmaceutical companies including GlaxoSmithKline (GSK) have 
committed to publish their CSRs. This commitment extends back to the formation 
of GSK in 2000. CSRs will be published for trials of approved or discontinued GSK 
drugs. They are posted onto a register, with personal information removed to 
maintain the privacy of participants.[117] The first CSRs were posted by the end of 
2013. Other companies including Roche have committed to provide CSRs and other 
summary reports on demand. In addition, the website ClinicalStudyDataRequest.
com was launched in 2013, which can be used by researchers to request access 
to anonymized patient level data and supporting documents to conduct further 
21
General introduction 1
research.[118] Study sponsors who have committed to use this site are Bayer, 
Boehringer Ingelheim, GSK, Lilly, Novartis, Roche, Sanofi, Takeda, UCB and ViiV 
Healthcare, while other companies elected to join other data access systems.[119] 
Researchers can submit research proposals and request anonymized data from 
studies listed on ClinicalStudyDataRequest.com, or submit enquiries to sponsors 
to ask for data from studies that are not listed. Proposals are reviewed by an 
independent review panel and sponsors are not involved in decisions made by 
the panel. Following approval and after the sponsor has received a signed data 
sharing agreement, access to the data is provided.[118] In the first 12 months 
after the system was launched, 36 submitted proposals were approved by the 
independent review panel, of which 23 had progressed to a signed data sharing 
agreement.[120] In parallel with these developments, the EMA has decided that, for 
all new centralized drug marketing authorizations submitted after 1 January 2015, 
it will provide public access to the core content of CSRs and will allow researchers 
to download and use the reports for further analyses.[121] The same policy will 
apply from 1 July 2015 to applications that are submitted to seek authorization 
for new indications of already approved drugs. In the future, the EMA intends to 
also provide access to anonymized individual patient data from its database.[121]
Aims and outline of this thesis
The quality of clinical drug trials and especially the influence of the pharmaceutical 
industry on the clinical trial process are currently of great interest. However, 
previous research has often focused on either industry-sponsored or non-profit 
trials, and the number of systematic comparisons between both types of studies is 
limited. The aim of this thesis was to further investigate the influence of the funding 
source in clinical drug research by conducting a series of studies that focused on 
different aspects of trial quality. 
Before clinical trials can be started, protocols need to be approved by research 
ethics committees (RECs). The objective of Chapter 2 was to identify shortcomings 
in protocols of drug trials based on comments that were raised during REC review 
and to assess whether these were more common among industry-sponsored or 
non-industry trials. Although numerous studies on publication bias have been 
undertaken, no standardized methodology for the classification of trial results 
22
Chapter 1
and sponsorship based on the information reported in published articles has 
been described. Dissimilarities in this assessment impede the ability to draw valid 
conclusions on the role of the sponsor in publication bias. Chapter 3 provides 
recommendations for a uniform method of classifying results and sponsorship. 
Publication bias is generally ascribed to authors and sponsors failing to submit 
studies with negative results, but may also occur after submission to journals. In 
Chapter 4, we analyzed manuscripts on drug trials submitted to eight medical 
journals. We evaluated whether articles were more likely to be accepted if they 
reported positive results and compared the proportion of submitted manuscripts 
with positive results by sponsor type. Using the same cohort of manuscripts, 
Chapter 5 describes the results of a study in which we compared the extent of 
discrepancies between trial information in registries and articles and the timing of 
registration by sponsor type. We assessed whether these discrepancies between 
registries and articles were decisive for rejection by journals. In Chapter 6, we 
performed a descriptive content analysis of peer review comments made on 
the same cohort of drug trial manuscripts. We investigated whether there was 
a relationship between the content of reviewer comments and sponsorship, 
direction of results, and decision about acceptance. In Chapter 7, we conclude 
with a general summary and discussion of the findings presented in this thesis and 
we describe the implications for future research on this topic. 
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Abstract
Background: Submission of study protocols to research ethics committees (RECs) 
constitutes one of the earliest stages at which planned trials are documented 
in detail. Previous studies have investigated the amendments requested from 
researchers by RECs, but the type of issues raised during REC review have not been 
compared by sponsor type. The objective of this study was to identify recurring 
shortcomings in protocols of drug trials based on REC comments and to assess 
whether these were more common among industry-sponsored or non-industry 
trials.
Methods: Retrospective analysis of 226 protocols of drug trials approved in 2010-
2011 by three RECs affiliated to academic medical centres in The Netherlands. 
For each protocol, information on sponsorship, number of participating centres, 
participating countries, study phase, registration status of the study drug, and 
type and number of subjects was retrieved. REC comments were extracted from 
decision letters sent to investigators after review and were classified using a 
predefined checklist that was based on legislation and guidelines on clinical drug 
research and previous literature. 
Results: Most protocols received comments regarding participant information 
and consent forms (n=182, 80.5%), methodology and statistical analyses (n=160, 
70.8%), and supporting documentation, including trial agreements and certificates 
of insurance (n=154, 68.1%). Of the submitted protocols, 122 (54.0%) were non-
industry and 104 (46.0%) were industry-sponsored trials. Non-industry trials 
more often received comments on subject selection (n=44, 36.1%) than industry-
sponsored trials (n=18, 17.3%; RR, 1.58; 95% CI, 1.01 to 2.47), and on methodology 
and statistical analyses (n=95, 77.9% versus n=65, 62.5%, respectively; RR, 
1.18; 95% CI, 1.01 to 1.37). Non-industry trials less often received comments on 
supporting documentation (n=72, 59.0%) than industry-sponsored trials (n=82, 
78.8%; RR, 0.83; 95% CI, 0.72 to 0.95). 
Conclusions: RECs identified important ethical and methodological shortcomings 
in protocols of both industry-sponsored and non-industry drug trials. Investigators, 
especially of non-industry trials, should better prepare their research protocols in 
order to facilitate the ethical review process.
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Background
Before new drugs can enter the market, they are extensively investigated in clinical 
trials. Also after registration, clinical drug research is important to improve our 
knowledge on safe and effective use of drugs.[1] In addition, drugs are frequently 
used as tools to investigate physiology and pathophysiology in humans in vivo. 
Prior to the recruitment of trial participants, research protocols need to be 
evaluated by research ethics committees (RECs) to assess whether all scientific, 
ethical, and legal requirements for conducting drug research with human subjects 
are met.[2, 3] Studies may raise questions of informed consent, adequate subject 
selection, scientific validity, acceptable risk-benefit ratios, and the value of the 
research to society in relation to the burdens to participants.[4] 
Submission of study protocols to RECs constitutes one of the earliest stages at 
which planned trials are documented in detail. Prior studies on ethical review of 
protocols involving human subjects have investigated the type of amendments 
and clarifications requested from researchers by RECs. For many protocols, 
some type of amendment was needed before approval.[5-7] RECs frequently 
commented on inadequacies in informed consent forms, possible risks to 
participants, methodological and statistical issues in protocols, and missing or 
incorrect supporting documentation.[5-10] However, several studies on REC 
review included small numbers of protocols [5, 9, 10], or focused on protocols 
submitted to single RECs so resulting findings may be specific to the committee 
studied [5, 6]. In addition, although the issues raised by RECs may depend on the 
intervention tested, previous studies have included protocols regardless of the 
type of intervention.[5-8, 10] 
The type and extent of shortcomings detected by RECs may also be related to 
sponsorship of trials. Pharmaceutical companies generally have larger budgets 
and a better research infrastructure compared to non-profit organizations, which 
could lead to higher protocol quality. However, it has also been suggested that 
the pharmaceutical industry’s pursuit of profit and favourable study results may 
have negative effects on research quality.[11, 12] Studies based on published trials 
have indicated that methodological quality is comparable for industry-sponsored 
and non-industry trials.[12-14] However, for a cohort of trials submitted to a Dutch 
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REC, it was shown that non-industry trials have more problems in recruiting the 
required number of subjects than studies initiated by pharmaceutical companies.
[15] This was confirmed in a study with protocols approved by RECs in Switzerland, 
Germany, and Canada indicating that industry-sponsorship was associated with 
lower rates of trial discontinuation due to poor recruitment.[16] The shortcomings 
of protocols that are identified during REC review have not been compared by 
sponsor type though.
The objective of this explorative study was to identify recurring shortcomings in 
protocols of drug trials and to assess whether these are more common among 
industry-sponsored or non-industry trials. Protocols submitted to three RECs 
affiliated to academic medical centres in The Netherlands were included and REC 
decision letters sent to researchers after review were accessed. REC comments 
were extracted and classified using a predefined checklist that was based on 
legislation and guidelines on clinical drug research and previous literature. It was 
examined whether there was a relationship between the occurrence of certain 
types of comments and industry sponsorship.
Methods
Selection of RECs and protocols
All eight RECs affiliated to academic medical centres in The Netherlands were 
asked to provide access to submitted protocols and their correspondence with 
investigators. These eight committees together review 70% of all medical research 
with human subjects conducted in The Netherlands.[17] RECs located in Nijmegen 
(CMO), Amsterdam (METc VUmc) and Leiden (CME) agreed to participate. Other 
committees did not participate due to logistical or confidentiality issues. All 
protocols approved in 2010-2011 were included, if they were classified as trials 
with medicinal products. 
Extraction of trial characteristics
For each protocol, information was retrieved on sponsor type, number of 
participating centres, participating countries, study phase, type of subjects, 
anticipated number of subjects, and whether the study drug was registered 
in The Netherlands. Data were extracted from a standardized form used in The 
37
Shortcomings of drug trials as identified by research ethics committees
2
Netherlands to prospectively document characteristics of planned trials (ABR 
form). Trials were classified as non-industry or industry-sponsored trials. For 
industry-sponsored trials, a pharmaceutical company was explicitly reported 
as the study sponsor in the ABR form. We verified whether the company indeed 
had the overall responsibility for the conduct of the trial using the trial protocol, 
clinical trial agreement and correspondence between the REC and investigators. 
Non-industry trials were investigator-initiated studies for which no associations 
with pharmaceutical companies were reported, or investigator-initiated studies 
that received study medication or financial support from manufacturers which did 
not have any responsibility for the content of the protocol.
Extraction and classification of REC comments
For the classification of REC comments, a comprehensive checklist was composed 
prior to accessing REC decision letters (Table 1). The content of this checklist was 
based on national and international legislation and guidelines on the conduct 
of drug research with human subjects, and previous literature on this topic [2-
4, 18-21]. This resulted in a checklist consisting of thirteen review criteria, that 
need to be considered by RECs to assess whether all scientific, ethical, and legal 
requirements for drug trials are met. For each trial, the issues raised by RECs were 
extracted from REC decision letters that were sent to investigators after protocol 
review. As these comments were not described in a standardized manner in REC 
letters, all data were first fully transcribed and subsequently categorized using 
the classification checklist. During the extraction of REC comments, there was no 
blinding for sponsorship as this was unfeasible due to logistical reasons. In this 
explorative study, the categorization of comments was performed by one author. 
Submitted protocols could be discussed by RECs at several occasions before 
receiving approval. All correspondence between RECs and investigators prior to 
approval was included in this study. Furthermore, the number of days between 
protocol submission and final REC approval was determined, which consisted of 
time attributable to RECs and time used by researchers to respond to comments.
Statistical analysis
The association between sponsor type and the number of trials that received 
comments after REC review was analyzed using generalized linear models (log-
binomial) for each of the thirteen review criteria. We controlled for the REC that 
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Table 1. Classification checklist for REC review of protocols of drug trials
Review Criteria Definition
1. Proportionality
Risks and burdens to subjects are reasonable in relation to 
anticipated benefits
Trial leads to important medical knowledge and/or 
considerable health benefits
Participation does not involve unacceptable/
disproportionate risks or burdens to subjects, use of 
placebo in trial is ethically justified
2. Minimisation of risks & burdens
Risks and burdens to subjects are minimized
Research question cannot be answered without inclusion 
of human subjects
Research question cannot be answered by more simple or 
less riskful/burdensome research
3. Privacy & confidentiality
Adequate provisions are made to protect privacy of 
subjects and maintain confidentiality of data and body 
tissues
Trial data and body tissues are adequately coded, stored 
and protected, with restricted access for third parties
4. Patient safety
Adequate provisions are made to ensure safety of subjects 
during the trial
Collected data are adequately monitored and (if necessary) 
a Data and Safety Monitoring Board (DSMB) is installed
Individual and group level stopping criteria are adequate 
5. Recruitment process
Recruitment methods and payments to subjects are 
acceptable 
Investigator has access to population that allows 
recruitment of required number of subjects
Subjects are given adequate opportunity and time to ask 
questions and decide about participation
6. Information sheet & consent 
form
Subject information sheet & consent form contain all 
required elements
The length, structure and language use of the information 
sheet & consent form will allow subjects to understand 
them correctly
7. Subject selection
Subject selection is appropriate to answer the research 
question
Inclusion and exclusion criteria are adequate and 
complete, equity in subject selection
8. Protection vulnerable subjects
When vulnerable subjects are included, there are 
additional safeguards to protect their rights and well-being
No vulnerable subjects are included, unless they may 
benefit themselves from participation or trial cannot be 
conducted without them
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reviewed the protocol by including both sponsor type and REC as predictors in 
the model, and tested for interaction between sponsor type and REC. Associations 
between sponsor type and the number of trials that received comments were 
estimated with relative risks (RRs) and 95% confidence intervals (CIs). The total 
time between protocol submission and REC approval was compared by sponsor 
type and REC using a two-way ANOVA. We tested for interaction between 
sponsor type and REC. As time to approval was positively skewed, data were Ln-
transformed before testing for differences between groups. P<.05 was considered 
statistically significant. Because of the explorative character of this study, P-values 
were not adjusted for multiple comparisons. Statistical analyses were performed 
using SPSS software (version 20; Chicago, Illinois).
Ethics
To assure confidentiality of information in submitted protocols and 
correspondence between RECs and investigators, confidentiality agreements 
9. Methodology & statistical 
analysis
Trial design/methodology is appropriate and properly 
motivated in protocol 
Selected primary & secondary endpoints and dosage 
regimen are appropriate
Sample size calculations and planned statistical analyses 
are adequate
10. Product information
Product information on the medicinal product(s) used in 
the study is adequate
Investigator’s Brochure (IB) and Investigational 
Medicinal Product Dossier (IMPD)/ Summary of Product 
Characteristics (SPC) are acceptable
11. Supporting documentation 
Other documents submitted as part of the research 
proposal are acceptable
Data in ABR form are complete and correct and the Clinical 
Trial Agreement is in accord with Dutch regulations 
Required insurances for medical research with human 
subjects are arranged
12. Facilities & research staff
Research staff members are experienced and qualified to 
conduct trial procedures
Investigator has adequate facilities to conduct the trial
13. Financial aspects
All costs incurring during the trial are adequately covered
Compensation fees paid to investigators or institutions are 
proportional to the size, nature, and purpose of the trial
Conditions (e.g. financial interests) leading to conflicts of 
interest are prevented
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were signed before gaining access to the data. As standard REC procedures 
were unchanged, investigators were not informed about this study. Formal REC 
approval was not required for this study as no human subjects were involved.
Results
In 2010 and 2011, 226 protocols of drug trials were approved by three Dutch RECs 
(Nijmegen, n=74; Amsterdam, n=76; Leiden, n=76) (Table 2). In 2010, 123 (54.4%) 
protocols were approved, compared to 103 (45.6%) in 2011. Of the submitted trials, 
104 (46.0%) were sponsored by the pharmaceutical industry and 122 (54.0%) were 
non-industry trials, of which 31 were financially or materially supported by a for-
profit organisation (13.7% of the total number of trials). 
Most studies were multicentre trials (n=126; 55.8%) and were mostly conducted in 
The Netherlands only (n=131; 58.0%) (Table 2). 31 of the 126 multicentre studies 
(24.6%) were performed in The Netherlands only, whereas 95 (75.4%) were 
multinational multicentre studies. Trials were categorized as phase 1 (n=21; 9.3%), 
phase 2 (n=62; 27.4%), phase 3 (n=62; 27.4%), phase 4 (n=17; 7.5%), or other trials 
involving medicinal products (n=64; 28.3%). In 50 trials (22.1%), a drug registered 
in The Netherlands for the same indication/dosage as studied in the trial protocol 
was used, while 74 (32.7%) used drugs that were registered for a different 
indication/dosage than studied in the protocol, and 79 (35.0%) used drugs that 
were not registered in the Netherlands. For 23 trials (10.2%), it was not reported 
whether the study drug was registered. Most trials recruited adult subjects capable 
of giving informed consent (n=208; 92.0%), while 7 (3.1%) trials included adult 
subjects not capable of giving informed consent and/or minors <18 years, and 11 
(4.9%) included both types of subjects. The median number of subjects per trial 
was 59 (interquartile range (IQR), 24-240). The median number of subjects in trials 
conducted in The Netherlands only was 34 (IQR, 20-60), compared to 300 (IQR, 
120-800) in multinational trials. 
In Table 3, random examples of comments raised during REC review are presented 
to illustrate each type of shortcoming. Table 4 shows the number of trials that 
received comments for each of the review criteria. Most trials received comments 
on the subject information sheet and consent form (n=182, 80.5%), methodology 
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Table 2. Characteristics of drug trials approved in 2010-2011
Protocols
Total, n (%) 226 (100)
REC
Nijmegen 74 (32.7)
Amsterdam 76 (33.6)
Leiden 76 (33.6)
Year of approval
2010 123 (54.4)
2011 103 (45.6)
Sponsor type
Non-industry 91 (40.3)
Non-industry, supported by industry 31 (13.7)
Industry-sponsored     104 (46.0)
Number of centres
Single centre 100 (44.2)
Multicentre 126 (55.8)
NL only or international trial
NL trial 131 (58.0)
International trial 95 (42.0)
Phase
Phase 1 21 (9.3)
Phase 2   62 (27.4)
Phase 3 62 (27.4)
Phase 4 17 (7.5)
Other 64 (28.3)
Study drug registered in NL
Yes, for the same indication/dosage as studied in protocol 50 (22.1)
Yes, for different indication/dosage than studied in protocol 74 (32.7)
No 79 (35.0)
Not reported whether drug was registered in NL 23 (10.2)
Type of subjects
Adult subjects capable of giving informed consent 208 (92.0)
Adult subjects not capable of giving informed consent and/or minors <18 
years
7 (3.1)
Adult subjects capable of giving informed consent and adults not capable of 
giving informed consent or minors <18 years
11 (4.9)
Anticipated number of subjects, median (IQR) 
Number of subjects (total) 59 (24-240)
Number of subjects (NL trials) 34 (20-60)
Number of subjects (international trials) 300 (120-800)
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Table 3. Examples of REC comments on protocols of drug trials
Review Criteria Example
1. Proportionality
 
“The committee has serious doubts regarding the proportionality 
of the study, because the trial is very burdensome for participants 
and a number of potentially risky interventions are being 
combined.” 
“The committee would like to hear the expected benefit(s) of the 
study drug from the investigators; the clinical relevance of the 
trial is not clear.”
2. Minimisation of risks & 
burdens
 
“The committee wonders why it is necessary to burden patients 
with completion of the proposed quality of life questionnaires; 
much is already known about the quality of life of this group of 
patients.”
“The investigators need to convince the committee of the 
usefulness of repeating skin biopsies and synovial biopsies.”
3. Privacy & confidentiality
 
“The committee notes that questionnaires should be stored 
coded; there should be no personal data on the questionnaires, 
as is the case now for a number of questionnaires.”
“Trial medication is home delivered to participants by courier; the 
committee wants to know which provisions are made to prevent 
that participant addresses are known by the manufacturer.” 
4. Patient safety
 
“The committee wonders why no individual and group level 
stopping rules are defined and no DSMB is installed for this trial.”
“The committee wonders whether it is possible, in view of patient 
safety, to sequentially include participants in this trial.”
5. Recruitment process
 
“The minimal time of 24h to decide about participation is 
too short considering the chance of placebo treatment, and 
the potential risks and burdens of participating; it should be 
minimally 5 days.” 
“The committee is concerned whether enough patients can be 
included; this type of cancer is particularly seen in patients with 
metastases, but these patients cannot participate in the trial.”
6. Information sheet & 
consent form
“The written subject information is too long and too difficult 
(regarding both vocabulary and style); the committee would 
like to see a completely rewritten version, understandable to a 
layperson.” 
“It should be more clearly explained to which extent the trial 
treatment deviates from the standard treatment and what 
subjects must undergo additionally by participating in the trial.”
7. Subject selection
“The committee asks the investigators why they do not select 
subjects at inclusion based on pain complaints, while this is an 
objective of the trial.”
“The committee has the impression that the exclusion criteria 
are not complete, considering the SPC text; in particular, the 
committee believes that children with heart disease or kidney 
failure should be excluded.”
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and planned statistical analyses (n=160, 70.8%), and supporting documentation, 
including clinical trial agreements and certificates of insurance (n=154, 68.1%). 
In contrast, RECs rarely commented on the minimization of risks and burdens 
to subjects (n=26, 11.5%), financial aspects (n=39, 17.3%), and the protection of 
vulnerable subjects (n=9, 4.0%). 
8. Protection vulnerable 
subjects
“The committee would like to hear substantive arguments for the 
need to include minors; the investigators have not justified why 
this group should be involved in this trial.”
“The committee would like to hear how subjects and their 
relatives are informed on the procedures in case of resistance by 
subjects during the trial.”
9. Methodology & statistical 
analysis
“The sample size calculation does not reflect the primary 
analysis described as a (mixed effect) repeated measures ANOVA; 
the current calculation does not reflect that there are 10 VAS pain 
measurements.”
“The trial is designed as cross-over; because of potential carry-
over effects, the committee believes that a parallel comparison 
of 2 groups should be preferred.” 
10. Product information
“The committee needs more information on the endothelin 
receptor antagonists; information on product characteristics, 
pharmacological characteristics, efficacy and safety, and 
pharmacokinetics is missing.”
“The data in the IMPD are from 1997; the committee wants to 
know whether this batch is still being used or whether there has 
been a more recent production.”  
11. Supporting 
documentation
“The text in the Clinical Trial Agreement on (premature) 
termination of the trial and publication of results does not 
correspond to provisions in the Dutch regulation on assessment 
of Clinical Trial Agreements.”
“The committee wants to know whether the sponsor takes 
responsibility for the clinical trial liability insurance for all 
participating centres.”
12. Facilities & research 
staff
“A student cannot be principal investigator for this trial, because 
a student lacks experience and cannot take final responsibility 
for the trial.”  
“The committee believes that, considering the treatment during 
the trial, an oncologist should be involved in the design and 
conduct of the trial.”
13. Financial aspects
“The committee would like to see an exact justification of the 
100.000 euro that the department will receive for conducting the 
trial.”
“The committee does not agree with the independent physician 
appointed for 3 of the participating centres; this person also 
works as a physician for the pharmaceutical company sponsoring 
this trial.”
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Non-industry trials more often received comments on subject selection (n=44, 
36.1%) than industry-sponsored trials (n=18, 17.3%; RR, 1.58; 95% CI, 1.01 to 
2.47) (Table 4). More non-industry trials received comments on methodology 
and statistical analyses (n=95, 77.9%) compared to industry-sponsored trials 
(n=65, 62.5%; RR, 1.18; 95% CI, 1.01 to 1.37). In contrast, non-industry trials less 
often received comments on supporting documentation (n=72, 59.0%) than 
industry-sponsored trials (n=82, 78.8%; RR, 0.83; 95% CI, 0.72 to 0.95). There was 
a non-significant trend indicating that non-industry trials more often received 
comments related to facilities and research staff (n=39, 32.0%) compared to 
industry-sponsored trials (n=18, 17.3%; RR, 1.60; 95% CI, 0.98 to 2.60). The 
proportion of trials that received comments was comparable between RECs for 
protection of vulnerable subjects and product information. For the other review 
criteria, the proportion of trials with comments was significantly different between 
RECs (data not shown). For product information and supporting documentation, 
the interaction between sponsor type and REC was p<.05. However, RRs for the 
association between sponsorship and these review criteria were comparable for 
the individual RECs and the interaction was considered not relevant with regard 
to the effect of sponsorship.
The median time to protocol approval was 112 days (IQR, 78-163) (Table 5). Time 
to approval was not significantly different between industry-sponsored (119 
days; IQR, 84-169) and non-industry trials (101 days; IQR, 75-158, p=.298). Time to 
approval was longer for protocols submitted in Nijmegen (148 days; IQR, 89-203) 
than for those submitted in Amsterdam (113 days; IQR, 87-150) or Leiden (91 days; 
IQR, 65-127, overall p=.000). There was no interaction between sponsor type and 
REC regarding time to approval.
Discussion
In this study, recurring shortcomings in protocols of drug trials were identified 
based on REC comments and it was assessed whether these were more common 
among industry-sponsored or non-industry trials. Most protocols received 
comments regarding informed consent forms, methodology and planned 
statistical analyses, and supporting documentation including clinical trial 
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Table 4. Analysis of REC comments - Non-industry (n=122) vs industry-sponsored trials 
(n=104)
Review Criteria
Protocols with 
comments, n (%)
Relative risk 
(95% CI)* P-value
1. Proportionality 61 (27.0)
Non-industry 34 (27.9) 0.95 (0.62-1.45) .805
Industry 27 (26.0)
2. Minimisation of risks & burdens 26 (11.5)
Non-industry 15 (12.3) 0.92 (0.44-1.91) .820
Industry 11 (10.6)
3. Privacy & confidentiality 63 (27.9)
Non-industry 29 (23.8) 0.93 (0.65-1.34) .695
Industry 34 (32.7)
4. Patient safety 61 (27.0)
Non-industry 36 (29.5) 1.31 (0.84-2.04) .228
Industry 25 (24.0)
5. Recruitment process 47 (20.8)
Non-industry 30 (24.6) 1.05 (0.63-1.73) .866
Industry 17 (16.3)
6. Information sheet & consent form 182 (80.5)
Non-industry 100 (82.0) 1.04 (0.94-1.13) .468
Industry 82 (78.8)
7. Subject selection 62 (27.4)
Non-industry 44 (36.1) 1.58 (1.01-2.47) .045
Industry 18 (17.3)
8. Protection vulnerable subjects 9 (4.0)
Non-industry 6 (4.9) 1.53 (0.38-6.07) .549
Industry 3 (2.9)
9. Methodology & statistical analysis 160 (70.8)
Non-industry 95 (77.9) 1.18 (1.01-1.37) .038
Industry 65 (62.5)
10. Product information 65 (28.8)
Non-industry 38 (31.1) 1.16 (0.75-1.78) .507
Industry 27 (26.0)
11. Supporting documentation 154 (68.1)
Non-industry 72 (59.0) 0.83 (0.72-0.95) .006
Industry 82 (78.8)
12. Facilities & research staff 57 (25.2)
Non-industry 39 (32.0) 1.60 (0.98-2.60) .060
Industry 18 (17.3)
13. Financial aspects 39 (17.3)
Non-industry 25 (20.5) 1.65 (0.90-3.01) .103
Industry 14 (13.5)
* Relative risks are controlled for the REC that reviewed the protocol.
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agreements and certificates of insurance. This corresponds to findings of previous 
studies on the issues raised by RECs.[5-7, 9] In addition, a recent evaluation of 
the Dutch law on medical research with human subjects also indicated that RECs 
give a lot of attention to improvement of participant information.[22] RECs rarely 
addressed the minimization of risks and burdens to subjects, financial aspects, 
and the protection of vulnerable subjects. The last finding is hardly surprising, as 
90% of the protocols included adult subjects capable of giving informed consent.
Non-industry protocols more often received comments related to methodology 
and statistical analyses and the selection of participants than industry-sponsored 
protocols, while research based on published trials indicated that methodological 
quality was comparable for industry-sponsored and non-industry trials.[12-
14] RECs may play an important role in improving the quality of submitted 
protocols, which could explain the observed absence of substantial differences 
in methodological quality in relation to sponsorship among published trials. In 
contrast, industry-sponsored trials more often received comments on supporting 
documentation submitted alongside protocols. This difference seemed to be 
associated with REC comments on clauses in clinical trial agreements for industry-
sponsored trials, in particular regarding the publication of results and premature 
termination of trials. 
Table 5. Time to approval of submitted protocols
Time to approval in days, 
median (IQR) P-value
Total protocols (n=226) 112 (78-163)
Sponsor type .298
Non-industry (n=122) 101 (75-158)
Industry-sponsored (n=104) 119 (84-169)
REC .000
Nijmegen (n=74) 148 (89-203)
Amsterdam (n=76) 113 (87-150)
Leiden (n=76) 91 (65-127)
Nijmegen vs Amsterdam .026
Nijmegen vs Leiden .000
Amsterdam vs Leiden .001
47
Shortcomings of drug trials as identified by research ethics committees
2
The time to protocol approval was comparable for non-industry and industry-
sponsored trials, but was significantly different between RECs. Time to approval 
may be related to the quality and characteristics of submitted protocols, but may 
also reflect the efficiency of the review process. The REC in Nijmegen received 
lower proportions of industry-sponsored studies and trials with drugs not 
registered in The Netherlands. There may be other differences between submitted 
protocols that were not detected in this study. In Leiden and Amsterdam, protocols 
are reviewed by science committees before submission to the REC, which may 
reduce the time needed by RECs to review methodological aspects. In addition, 
investigators submitting protocols to the REC in Leiden are invited to discuss 
their study with a pre-advisor prior to REC meetings. In The Netherlands, RECs 
should complete reviews of drug trials within sixty days.[18] The clock stops when 
RECs ask questions to investigators, and restarts when the required information 
is provided. However, as time to approval consisted of time attributable to RECs 
and time used by researchers to respond to comments, no definite conclusions 
can be drawn.
Due to the retrospective design of this study, included protocols were already 
reviewed before RECs were asked to participate in this study and the behaviour 
of REC members was not influenced by awareness of an ongoing investigation. 
As we had unrestricted access to submitted protocols and correspondence 
between RECs and researchers, we were able to extract trial characteristics and 
REC comments without having to obtain permission from researchers or rely on a 
survey of researchers to obtain these data, excluding the introduction of response 
bias.[23] Although there was no response bias with respect to individual studies, 
there may be a response bias in terms of RECs if the committees that declined 
to take part somehow differed from participating committees. Nevertheless, by 
inclusion of protocols submitted to three RECs that are among the eight largest 
committees in The Netherlands regarding the number of studies annually 
reviewed, more than 20% of all drugs trials approved in The Netherlands in 2010-
2011 were evaluated.
Many studies have focused on the methodological quality of published trials [12-
14] or followed protocols approved by RECs until publication.[23, 24] In contrast, 
we identified shortcomings of protocols based on REC comments raised prior to 
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trial initiation. Quality assessments in previous studies may have been affected 
by incomplete reporting in published articles, as evaluations of the risk of bias 
in trials may have been confused with assessment of the adequacy of reporting.
[25] REC comments may not inherently provide an objective reflection of the 
quality of submitted protocols, as it has been shown that REC review is variable 
regarding the decisions made on protocols.[26-28] Comments that are raised may 
be influenced by local variation in requirements, and may vary by REC even for 
the same protocol with multicenter trials.[28, 29] In this study, the proportion of 
protocols that received comments varied by REC for most of the review criteria. It 
is difficult to determine whether this reflects variable protocol quality or variable 
review by RECs.
This study has certain limitations. First, we focused on protocols submitted to 
Dutch RECs. In addition to the variability found between RECs within the same 
country, ethical review processes also vary between countries.[30, 31] This limits 
the generalizability of our findings to non-Dutch RECs, although 40% of the 
included trials were conducted in multiple countries. This study included trials 
that eventually received a favourable opinion. We did not evaluate protocols 
that were rejected by RECs. Although only 3% of all trials annually reviewed in 
The Netherlands are rejected [17], it may be interesting to consider this group as 
the chance of rejection might be associated with sponsorship. However, this was 
beyond the scope of the current study.
In this explorative study, the categorization of REC comments was performed by 
one author, while this would ideally have been done by two or more independent 
assessors and disagreements resolved by consensus. The categorisation of REC 
comments may be considered as subjective. However, to our knowledge, this is 
the first study in which shortcomings of protocols of drug trials as identified by 
RECs have been compared by sponsor type. The internal and external validity of 
the classification checklist used in this study could be further verified in future 
studies with different assessors and different samples of research protocols 
submitted to RECs.
Finally, industry-sponsored and non-industry trials may not be similarly addressed 
by RECs. Pharmaceutical companies commonly perform large multinational 
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trials, while non-industry trials are more often initiated and conducted by local 
investigators. In this study, 90% of the industry-sponsored trials were multicenter 
studies, compared to 30% of the non-industry trials. RECs that are involved at a 
single site of a large multicenter trial might feel constrained in their ability to modify 
the trial design and limited in what changes they can make to informed consent 
forms. In addition, multinational industry trials may have already implemented 
comments from RECs in other countries before submission to Dutch RECs.
In conclusion, RECs identified important ethical and methodological shortcomings 
in protocols of both industry-sponsored and non-industry drug trials. Investigators, 
especially of non-industry trials, should better prepare their research protocols in 
order to facilitate the ethical review process.
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Abstract
Background: Numerous studies on publication bias in clinical drug research 
have been undertaken, particularly on the association between sponsorship 
and favourable outcomes. However, no standardized methodology for the 
classification of outcomes and sponsorship has been described. Dissimilarities 
and ambiguities in this assessment impede the ability to compare and summarize 
results of studies on publication bias. To guide authors undertaking such studies, 
this paper provides recommendations for a uniform assessment of publication 
bias related to funding source.
Methods and Results: As part of ongoing research into publication bias, 472 
manuscripts on randomised controlled trials (RCTs) with drugs, submitted to 
eight medical journals from January 2010 through April 2012, were reviewed. 
Information on trial results and sponsorship was extracted from manuscripts. 
During the start of this evaluation, several problems related to the classification 
of outcomes, inclusion of post-hoc analyses and follow-up studies of RCTs in the 
study sample, and assessment of the role of the funding source were encountered. 
A comprehensive list of recommendations addressing these problems 
was composed. To assess internal validity, reliability and usability of these 
recommendations were tested through evaluation of manuscripts submitted to 
journals included in our study.
Conclusions: The proposed recommendations represent a first step towards a 
uniform method of classifying trial outcomes and sponsorship. This is essential to 
draw valid conclusions on the role of the funding source in publication bias and 
will ensure consistency across future studies.
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Background
In recent years, the issue of publication bias in clinical drug research has been 
widely addressed. Studies reporting results that are positive or favourable to 
the experimental drug are more likely to be published, and outcomes that are 
statistically significant have higher odds of being fully reported [1-3]. Funding by 
the pharmaceutical industry and financial conflicts of interest among authors 
have particularly been associated with publication of favourable outcomes [4-6]. 
Publication bias could result from researchers and sponsors failing to submit trials 
with negative results, or from favouritism towards publication of positive results 
among peer reviewers, journal editors and publishers.
Numerous studies on the association between sponsorship and trial outcomes 
have been undertaken [6]. Classification of outcomes as positive or negative and 
establishing the role of the funding source may appear to be straightforward. 
However, when reviewing studies on publication bias, no standardized 
methodology for the assessment of outcomes and sponsorship has been 
described. Definitions used for classification of trial outcomes are inconsistent 
across studies and the terms ‘sponsored by industry’ and ‘conflict of interest’ have 
been applied in different ways.
In a majority of the studies on publication bias, methods for classification of trial 
outcomes are only reported to a very limited extent, though there are positive 
exceptions [5, 7]. However, this assessment is not without hurdles, for instance 
when reviewing results of non-inferiority or equivalence trials and trials reporting 
safety rather than efficacy outcomes. Some studies concentrate on results reported 
for primary endpoints, while others examine conclusion sections to classify 
outcomes. Some investigators briefly mention that included trials are categorized 
according to funding source [7-9], while in other papers explicit criteria are given 
for the classification based on sponsor type. Drug trials are often considered to be 
industry-sponsored when funded by a pharmaceutical company [6, 10-12], while 
some researchers also regard donation of study medication by a manufacturer as 
industry-sponsorship [6, 10, 11, 13]. In addition, drug trials are sometimes classified 
as industry-sponsored if authored by one or more employees of the company 
manufacturing the test drug [10, 11, 13, 14]. Furthermore, the terms industry-
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funded, industry-supported, and industry-sponsored are used interchangeably 
when categorizing trials according to sponsorship.
Dissimilarities and ambiguities in the classification of outcomes and sponsorship 
impede the ability to compare and summarize results of studies on publication 
bias. A standardized approach, taking into account different types of financial and 
material support and a clear definition of trial outcomes, is essential to draw valid 
conclusions on the role of the funding source in publication bias. To guide authors 
undertaking studies on the association between sponsorship and study outcomes 
or authors undertaking systematic reviews or meta-analyses of such studies, this 
paper provides recommendations for a uniform assessment of publication bias 
related to funding source.
Methods
As part of ongoing research into biased reporting of trial outcomes, we assessed 
the role of editorial and peer review processes in publication bias. We evaluated 
whether submitted manuscripts with negative outcomes were less likely to be 
published than studies with positive outcomes, and determined the influence of 
sponsorship in this context. We retrospectively reviewed manuscripts submitted to 
eight journals from January 2010 through April 2012. One general medical journal 
(British Medical Journal) and seven specialty journals (Annals of the Rheumatic 
Diseases, British Journal of Ophthalmology, Diabetologia, Gut, Heart, Journal of 
Hepatology, and Thorax) were included. Journals were selected based on impact 
factor ( journals indexed with the highest impact factors within subject categories, 
according to Institute for Scientific Information Journal Citation Report 2011), 
and the number of drug RCTs published in 2010-2011. Manuscripts reporting 
results of RCTs were included, if at least one study arm assessed the efficacy or 
safety of a drug intervention and a statistical test was used to evaluate treatment 
effects (n=472). Two authors (MvL, HJO) extracted information on trial results and 
financial or material support from manuscripts. 
During the start of this evaluation, we encountered several problems related 
to (1) the classification of outcomes, (2) inclusion of post-hoc and subgroup 
analyses and follow-up studies of RCTs in the study sample, and (3) assessment 
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of the role of the funding source. These problems hampered unequivocal 
judgment on sponsorship and the direction of trial outcomes. We composed a 
list of recommendations addressing these problems, to facilitate a standardized 
assessment of manuscripts included in our study and future studies on publication 
bias. To assess internal validity, reliability and usability of the recommendations 
were tested through evaluation of manuscripts submitted to journals included in 
our study. Minor adjustments were made during this process, and a comprehensive 
list of recommendations was created.
Findings
Identified problems
Classification of trial outcomes
Poorly described methodology and lack of (or multiple) primary 
endpoints 
A poor description of trial design in research papers complicates the selection of 
manuscripts that are eligible for inclusion when conducting a study on publication 
bias. As trial outcomes are often classified based on results for reported primary 
endpoints, failure to accurately define a primary endpoint among a plurality of 
outcomes described or mentioning multiple primary endpoints constitutes a 
problem. Guidelines for accurate reporting of RCTs are available by means of the 
CONSORT Statement (Consolidated Standards of Reporting Trials) [15], but the 
quality of reporting regarding these and other aspects remains sub-optimal after 
publication of CONSORT recommendations [16, 17]. 
Safety as primary endpoint 
An issue not related to the adequacy of reporting, but to the type of outcomes 
reported, is represented by trials with safety rather than efficacy as a primary 
endpoint. It could be argued whether trial results should be classified as positive 
when the test drug is proven to be as safe as the control treatment, or whether this 
would only be valid when less adverse events are reported for the test drug than 
for the comparator. Furthermore, it can be difficult to determine whether reported 
outcomes should be considered as efficacy or safety endpoints. 
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Non-inferiority and equivalence trials 
Problems related to trial design also apply to outcomes of non-inferiority and 
equivalence trials. In case non-inferiority or equivalence is established for 
treatments in these trials, outcomes could be considered positive, as they confirm 
the hypothesis of the trial. However, there are no clinically relevant differences 
between treatments with regard to the primary outcome of the trial, which could 
also be interpreted as a negative finding.
Inclusion of post-hoc analyses and follow-up studies of trials
It could be argued whether post-hoc and subgroup analyses and follow-up studies 
of RCTs should be included in studies on publication bias, next to original trial 
reports. Due to inadequate reporting on methodological aspects as described 
above, it can be difficult to discriminate between original reports and secondary 
analyses of trial data based on publications in the scientific literature. Unless 
original trial protocols are available, it is often not possible with a high degree of 
certainty to make judgments on what is post-hoc and what is not. However, post-
hoc and subgroup analyses and follow-up studies of RCTs could be equally prone 
to influences of sponsorship and direction of results on publication of studies. 
Role of the funding source
Different levels of support 
Assessment of the role of the funding source in drug trials is complex because 
of the variety of levels of involvement reported, ranging from financial support 
and donation of study medication by a pharmaceutical company, to input of the 
manufacturer in the trial design, conduct, data analysis and publication of results. 
Financial support from industry is often described as unrestricted educational 
grants, which suggests that funding was given without any predefined involvement 
of the funder. Furthermore, some trials are authored by one or more employees of 
the company manufacturing the test drug or funding the study.
Inadequate reporting of sponsorship 
The assessment of sponsorship can be complicated by the fact that some journals 
do not report funding sources or do not explain the sponsor’s role in a trial, and 
authors may not disclose received funding. Consequently, trials receiving industry 
funding could be falsely classified as non-industry. The CONSORT 2010 Statement 
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and the Uniform Requirements for Manuscripts Submitted to Biomedical Journals 
of the International Committee of Medical Journal Editors (ICMJE) [15, 18], both 
adopted by many journals, insist on reporting of information on funding sources 
and other support and the role of funders. However, not all authors adhere to 
these guidelines when submitting manuscripts, and even if authors do adhere to 
them, journal editors may not require the material to be reported.
Formal sponsorship 
It is often unclear based on the information reported in manuscripts whether 
trials should be regarded as investigator-initiated studies or that pharmaceutical 
companies qualify for formal sponsorship as defined in the ICH-GCP (International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use – Good Clinical Practice) guidelines [19]. According 
to these guidelines, a study sponsor is “an individual, company, institution, or 
organization which takes responsibility for the initiation, management, and/or 
financing of a clinical trial.” Therefore, financial support only does not necessarily 
imply formal sponsorship by the donor. In the public trial registries ClinicalTrials.
gov, EU Clinical Trials Register and ISRCTN Register, definitions for funding and 
sponsorship are not consistent across registries and do not unequivocally 
discriminate between trials formally sponsored by industry according to ICH-GCP 
guidelines, and those receiving only financial or material support.
Non-profit trials 
When absence of industry support is evident, it can subsequently be difficult to 
distinguish between trials sponsored by governmental sources versus other non-
profit organisations. Frequently, it is unclear which party carries responsibilities 
regarding quality and safety measures during trials. Furthermore, trials can be 
supported by non-industry organisations, that are owned by pharmaceutical 
companies.
Recommendations
Classification of trial outcomes
Outcomes of drug RCTs should be classified as positive if results for the primary 
endpoint (as reported) are statistically significant (p<0.05 or 95% confidence 
interval (CI) for difference excluding 0 or 95% CI for ratio excluding 1) and supports 
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the efficacy of the test drug; or negative if the result does not reach statistical 
significance or is statistically significant in the direction of the control treatment 
being more efficacious (Table 1). When a trial is designed as an equivalence or 
non‐inferiority study and the two treatments are equivalent, i.e. differences 
in treatment effects do not equal or exceed preset margins, results should be 
classified as positive. When treatments are equally effective regarding the primary 
endpoint and it is not clearly stated whether a trial was designed as superiority 
or non-inferiority trial, results should be classified as positive. For manuscripts 
describing a safety parameter as primary endpoint, trials in which the test drug 
is reported to be as safe or safer than the control treatment (either placebo or 
active comparator) should be considered as positive. When authors explicitly 
hypothesized that the test drug is expected to be less harmful than control, only 
trials reporting results that support the safety of the test drug should be classified 
as positive. If treatments are equally harmful, results should be classified as 
negative.
If no primary outcome is stated for a trial, or multiple primary endpoints are 
selected, results should be classified based on the statistical significance and 
direction of most (primary) outcomes (>50%). When two co-primary outcomes 
are stated, results for both endpoints should support the efficacy or safety of the 
test drug in order to classify a trial as positive. If results for only one of the two 
endpoints are statistically significant in favour of the test drug, results should be 
classified as negative. When treatment effects are not directly compared between 
groups in the statistical analysis (i.e. against baseline measurements in each 
treatment arm), results should be classified as positive if they are statistically 
significant in favour of the test drug. If uncertainty remains over the classification 
of trial outcomes, studies should be scored as negative, unless the overall tone of 
the conclusion section favours the test drug.
Inclusion of post-hoc analyses and follow-up studies of trials
Studies explicitly referred to as post-hoc or subgroup analyses and follow-up 
studies of single RCTs are eligible for inclusion in studies on publication bias, if 
they compare the efficacy or safety of treatments to which participants have been 
assigned in an RCT, but with regard to other (secondary) outcomes, limited to a 
specific part of the original study population, or with an extended follow-up in 
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these analyses. Post-hoc and subgroup analyses based on combined data of 
multiple RCTs should not be included.
Role of the funding source
Drug trials should be considered as non-industry studies when no associations with 
a pharmaceutical company can be identified in the trial manuscript. No author-
industry affiliations are reported, no manufacturer is named in the materials 
and methods section or acknowledgements for providing study medication or 
placebos free of charge, and no statements are made about financial support 
from pharmaceutical companies (Table 2). These RCTs are sponsored by 
governmental or other non-profit organizations, including universities, hospitals 
and foundations. 
Table 1. Classification of outcomes of drug RCTs based on results reported for primary 
endpoints
Positive 
outcome
Negative 
outcome
Results for primary endpoint statistically significant and supporting the 
efficacy of test drug
X
Results for primary endpoint do not reach statistical significance X
Results for primary endpoint statistically significant in direction of 
control treatment being more efficacious
X
Treatments equivalent regarding primary endpoint in non-inferiority or 
equivalence trials
X
Treatments equally effective regarding primary endpoint in trials not 
explicitly described as superiority or non-inferiority study
X
Test drug as safe or safer than control treatment in trials with safety 
parameter as primary endpoint
X
Treatments equally harmful in trials with safety parameter as primary 
endpoint, when hypothesized that test drug is expected to be safer than 
control
X
Results for >50% of (primary) endpoints statistically significant in favour 
of test drug, when no/multiple primary endpoints are reported
X
Results for one primary endpoint statistically significant in favour of test 
drug, when two co-primary endpoints are reported
X
Treatment effects not compared between groups but against baseline in 
each arm; results for primary endpoint statistically significant in favour 
of test drug
X
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Trials should be classified as industry-sponsored when a pharmaceutical company 
is explicitly described as study sponsor in the manuscript, or when the company 
funding the trial is reported to have participated in the study design, data 
Table 2. Classification of drug RCTs according to sponsor type
Non-
industry 
trial
Industry-
supported 
trial
Industry-
sponsored trial 
1. Pharmaceutical company explicitly 
reported as study sponsor in 
manuscript
X
2. Company funding the trial participated 
in design, conduct, analysis, writing of 
article and/or decision to publish
X
3. Trial funded by industry and author(s) 
affiliated to industry, but role of 
funding source not reported
X
4. Financial support received from 
pharmaceutical company
X
5. Donation of study medication or 
placebos by manufacturer
X
6. One or more authors employed 
by pharmaceutical company 
manufacturing the test drug
X
7. Trial supported by non-profit 
organisation owned by pharmaceutical 
company
X
8. Investigator-initiated post-hoc analysis 
of single RCT formally sponsored by 
industry
X
9. Pharmaceutical industry not in any 
way involved in trial
X
Formal study sponsor according to ICH-GCP 
guidelines
Non-profit 
organisation
Non-profit 
organisation
Pharmaceutical 
company
Responsible party for quality and safety 
measures during trial
Non-profit 
organisation
Non-profit 
organisation
Pharmaceutical 
company
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collection, analysis, preparation of the manuscript, and/or decision to publish. 
Involvement of authors employed by a pharmaceutical company is indicative of 
industry sponsorship, but not sufficient to qualify a trial as industry-sponsored. 
Studies reporting donation of study medication or receipt of financial support 
by a pharmaceutical company, and trials with one or more authors employed 
by the company manufacturing the test drug should be assigned to a separate 
class of industry-supported trials. Solely provision of grants or drugs does not fully 
comply with criteria for sponsorship according to ICH-GCP guidelines, and thus 
differs from formal sponsorship by a pharmaceutical company. However, when 
a trial is funded by industry and there are company-employed co-authors, the 
company will likely participate in the conduct and reporting of the trial. These 
trials should be classified as industry-sponsored, if the role of the funding source 
is not explicitly reported. Trials funded or otherwise supported by a non-profit 
organisation owned by a pharmaceutical company should be categorized as 
industry-supported. Investigator-initiated post-hoc analyses of single RCTs that 
were formally sponsored by industry should also be scored as industry-supported. 
When doubt remains over sponsorship and the trial is registered, information in 
the trial registry should take precedence over other sources of information.
Discussion
In this study, several problems related to the classification of outcomes and 
sponsorship were identified. We have formulated recommendations addressing 
these problems to facilitate a uniform assessment of manuscripts included in 
studies on publication bias.
In this article, we have focused on the assessment of publication bias related to 
funding source. However, the relationship between favourable outcomes and 
sponsorship is much more complex. Numerous systematic reviews have found 
that industry sponsorship is associated with results that are favourable to the 
product of the company funding the trial [4, 20, 21]. Besides publication bias, there 
are other ways by which outcomes may be influenced. Industry bias may occur 
through the choice of comparators, dosing and timing of comparisons, coding of 
events and selective data analysis, interpretation of data and selective outcome 
reporting [6, 21, 22]. Although we have concentrated on publication bias, our 
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recommendations are generally applicable to studies comparing industry versus 
non-industry trials in relation to favourable outcomes. Furthermore, we only 
considered drug RCTs, but the recommendations are equally relevant to device 
studies, as these are also often sponsored by companies with a financial interest 
in the study outcomes.
In our recommendations, reported results are classified as positive or negative. 
Trials in which primary endpoints are reached or study hypotheses are confirmed 
are considered to be positive. Possible alternatives to categorize trials would 
include ‘significant’ vs ‘non-significant’, or ‘favorable’ vs ‘unfavorable’ findings. 
However, use of these terms would impede the classification of non-inferiority 
or equivalence trials and studies with safety parameters as primary endpoint. We 
have not included a third ‘neutral’ category, as we aimed to keep the classification 
as straightforward as possible. Moreover, previous studies on publication bias 
found relatively low numbers of studies with neutral or unclear results [23-25], so 
we included these in the ‘negative’ category.
For the classification of outcomes, we have concentrated on results reported 
for the primary endpoint. However, in several studies on industry bias, trials are 
categorized as positive if the conclusion is favourable (i.e. the authors recommend 
the test drug), not the reported results [13]. In this article, we recommend to 
consider conclusions only when trials cannot be classified based on reported 
results. Previous studies reporting on concordance between study results and 
conclusions found that industry-sponsored trials were less concordant than 
non-industry studies [6]. This lack of concordance, and the finding that industry-
sponsored studies are more likely to have favourable conclusions [6], may be 
explained by the use of distorted presentation or ‘spin’ in papers [26]. As results 
may be more objective measures of treatment effects, we chose to concentrate on 
the assessment of results. Future studies on publication bias should clearly state 
whether trial results or conclusions are being examined. 
Trials were classified as non-industry, industry-supported or industry-sponsored. 
One of the most fundamental differences between industry-supported and 
industry-sponsored studies relate to the overall responsibility for the conduct 
of the trial as defined by ICH-GCP guidelines. Industry-supported trials are done 
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under the responsibility of non-profit organizations in contrast to industry-
sponsored studies. This distinction is usually not made in previous literature 
but is very relevant in terms of quality assessment of reported research. We have 
not included a category of ‘sponsorship not stated’. Many journals nowadays 
ask for information on received funding and the role of the funding source, and 
require that manuscripts on RCTs conform to ICMJE requirements and CONSORT 
guidelines. Therefore, most trials recently submitted should report on funding 
and be registered in a trial registry, making information on sponsorship traceable. 
However, the non-industry category may include trials that received industry 
support, if authors failed to disclose funding. In a recent Cochrane review on 
sponsorship and research outcomes, studies were also coded as non-industry 
if it was not reported who sponsored the study. The review authors stated that 
some of these trials were likely industry-sponsored, but no changes in results 
were seen when studies without sponsorship statements were excluded [6]. In 
addition, industry-sponsored studies may be misclassified as industry-supported, 
as apparently independently conducted industry-supported trials may have 
unreported sponsor involvement [27]. 
For future studies on publication bias, it is important that the quality of reporting 
on design and sponsorship of trials is improved. Journals should actively enforce 
the CONSORT Statement and ICMJE requirements, and could require authors 
to complete a form for disclosure of sponsorship and support received for the 
reported trial [28]. 
We emphasize that our recommendations are only validated for use by three 
investigators. In order to prove whether the recommendations are acceptable 
to researchers in general, it is essential that the external validity of this proposed 
classification system is determined in a study undertaken by different researchers 
on a different sample of manuscripts. To establish external validity, a Delphi 
consensus technique could be conducted among a larger group of researchers. 
Future research should focus on whether the classification system is adopted in 
practice by investigators undertaking studies on trial outcomes and sponsorship.
In conclusion, the recommendations proposed in this article represent a first step 
towards a uniform method of classifying trial outcomes and sponsorship. This is 
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essential to draw valid conclusions on the role of the funding source in publication 
bias and will ensure consistency across future studies.
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Abstract 
Background: Publication bias is generally ascribed to authors and sponsors failing 
to submit studies with negative results, but may also occur after submission. We 
evaluated whether submitted manuscripts on randomized controlled trials (RCTs) 
with drugs are more likely to be accepted if they report positive results.
Methods: Manuscripts submitted from January 2010 through April 2012 to 
one general medical journal (BMJ) and seven specialty journals (Annals of 
the Rheumatic Diseases, British Journal of Ophthalmology, Gut, Heart, Thorax, 
Diabetologia, and Journal of Hepatology) were included, if at least one study 
arm assessed the efficacy or safety of a drug and a statistical test was used to 
evaluate treatment effects. Publication status was retrospectively retrieved from 
submission systems or provided by journals. Sponsorship and trial results were 
extracted from manuscripts and classified according to predefined criteria. Main 
outcome measure was acceptance for publication. 
Results: Of 15,972 manuscripts submitted, 472 (3.0%) were drug RCTs, of which 
98 (20.8%) were published. Among submitted drug RCTs, 287 (60.8%) had positive 
and 185 (39.2%) negative results. Of these, 60 (20.9%) and 38 (20.5%), respectively, 
were published. Manuscripts on non-industry trials (n=213) reported positive 
results in 138 (64.8%) manuscripts, compared to 71 (47.7%) on industry-supported 
trials (n=149), and 78 (70.9%) on industry-sponsored trials (n=110). Twenty-seven 
(12.7%) non-industry trials were published, compared to 27 (18.1%) industry-
supported and 44 (40.0%) industry-sponsored trials. After adjustment for other 
trial characteristics, manuscripts reporting positive results were not more likely 
to be published (OR, 1.00; 95% CI, 0.61 to 1.66). Submission to specialty journals, 
sample size, multicentre status, journal impact factor, and corresponding authors 
from Europe or US were significantly associated with publication.
Conclusions: For the selected journals, there was no tendency to preferably 
publish manuscripts on drug RCTs that reported positive results, suggesting that 
publication bias may occur mainly prior to submission. 
75
Role of editorial and peer review processes in publication bias
4
Introduction
Publication bias refers to the selective publication of research findings depending 
on the nature and direction of results [1] and has been widely studied. Studies 
reporting positive results are more likely to be published [2-4], which may cause 
meta-analyses based on published reports to overestimate the size of apparent 
treatment effects. Pharmaceutical industry sponsorship has particularly been 
associated with publication of favourable outcomes.[5-8] Publication bias is 
generally ascribed to authors and sponsors failing to submit studies with negative 
results, but may also occur once manuscripts have been submitted to journals.
[9,10] 
A limited number of studies have systematically evaluated publication bias in 
editorial decision making. Olson et al. assessed manuscripts submitted to JAMA, 
and found no difference in publication rates between manuscripts with positive 
versus negative results.[11] Lee et al. found similar results for manuscripts 
submitted to BMJ, the Lancet and Annals of Internal Medicine.[12] Lynch et al. and 
Okike et al. assessed submissions to The Journal of Bone and Joint Surgery, and 
found no evidence for publication bias by editors.[13,14] Overall, these studies 
suggest that submitted manuscripts with positive results are not more likely to be 
published, which was confirmed by a recent meta-analysis.[15]
However, these studies had certain limitations. Most were prospective studies, 
so editors and reviewers may have been aware that some investigation was in 
progress.[11-13] This possibly influenced their decision making, even if they were 
not informed about the study hypothesis. Olson et al. and Lee et al. included large 
general medical journals with high impact factors, and their results may not be 
generalizable to specialty journals or journals with fewer submissions, fewer editors 
or lower circulation.[11] Two studies were limited to orthopaedic journals, and 
resulting findings may not apply to other specialties.[13,14] Moreover, publication 
bias may affect studies with various designs and interventions differently. Olson et 
al. included manuscripts on controlled trials, while others enrolled manuscripts 
reporting original research, regardless of study design.[12-14] None of the studies 
that followed manuscripts submitted to journals included papers based on the 
intervention tested, while publication bias has predominantly been researched 
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and described for drug trials.[4,6,7,16,17] 
Acceptance rates may also depend on sponsorship, next to study results. 
Publication of industry-sponsored trials has been associated with an increase 
in journal impact factors [18], as impact factors depend on citation rates and 
industry-sponsored trials are more frequently cited than non-profit trials.[19,20] 
Moreover, journals create revenue through reprint sales, and industry funding of 
trials has been associated with high numbers of reprint orders.[21,22] Lynch et al. 
found that commercially funded research was more likely to be published, while 
Olson et al. reported no difference according to funding source.[11,13] However, 
neither of these studies focused on drug research, in which industry funding 
appears to be most abundant. 
In this study, we retrospectively assessed manuscripts on randomized controlled 
trials (RCTs) with drugs submitted to one general medical journal and seven 
specialty journals, and evaluated acceptance rates of manuscripts reporting 
positive versus negative results. We hypothesized that negative trials were less 
likely to be published. Submission rates of positive versus negative studies were 
compared by sponsor type and the influence of sponsorship on acceptance rates 
was determined. 
Methods
Selection of journals
Editors of six major general medical journals were asked for their cooperation 
to provide access to submitted manuscripts, peer review comments, and final 
decisions on publication. BMJ agreed to participate and the BMJ Group also 
provided access to data of BMJ specialty journals. In addition, other European 
specialty journals were asked to participate. All journals were selected based on 
1. impact factor ( journals indexed with the highest impact factors within subject 
categories, according to the Institute for Scientific Information Journal Citation 
Report 2011); and 2. the number of drug RCTs published in 2010-2011, determined 
on the basis of a PubMed search. As a result, publication outcomes were studied 
for one general medical journal and seven specialty journals: BMJ, Annals of the 
Rheumatic Diseases, British Journal of Ophthalmology, Gut, Heart, Thorax (all 
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from the BMJ Group), Diabetologia, and Journal of Hepatology.
Selection of submitted manuscripts
Original research manuscripts submitted between January 1, 2010 and April 30, 
2012 were screened for eligibility by one author. The study time frame per journal 
was based on the retrospective period for which all required data, regardless of 
the publication status of manuscripts, was completely available in manuscript 
submission systems at the time of data extraction. Manuscripts reporting results 
of RCTs were selected, if at least one study arm assessed the efficacy or safety 
of a drug intervention (including vaccines, biologics, dietary supplements, and 
herbal medicinal products) and a statistical test was used to evaluate treatment 
effects. Post-hoc and subgroup analyses and follow-up studies of drug RCTs were 
included. 
Data extraction 
Data were extracted retrospectively by one author using a standardized data 
extraction form. Primary outcome was acceptance for publication. Publication 
status and peer review details were retrieved from submission systems or 
provided by journals. Manuscripts were assessed as outright rejected, rejected 
after external peer review, or accepted for publication. Information on trial results 
and sponsorship was extracted from manuscripts. Data on study characteristics 
previously examined for association with publication (sample size, number of 
centres, corresponding author’s country of residence [11-13] ) were also retrieved. 
Manuscripts were searched for registration numbers to determine whether 
studies were registered in a trial registry that complies with requirements of the 
International Committee of Medical Journal Editors (ICMJE).[23] All included 
journals required trial registration in their instructions to authors.
Classification of results and sponsorship
Trial results and sponsorship were classified based on consensus between two 
authors according to predefined criteria.[24] Briefly, outcomes were scored as 
positive if results reported for the primary endpoint were statistically significant 
(p<0.05 or 95% confidence interval (CI) for difference excluding 0 or 95% CI for ratio 
excluding 1) and supported the efficacy of the test drug, and negative if they did 
not. For equivalence and non-inferiority trials, results were classified as positive 
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if treatments were equivalent. If the primary endpoint was a safety parameter, 
trials were classified as positive if the test drug was as safe as or safer than control. 
When explicitly hypothesized that the test drug was expected to be safer than 
control, results were categorized as negative if treatments were equally harmful. 
If no primary outcome was stated for a trial or multiple primary endpoints were 
selected, results were classified based on the statistical significance and direction 
of most (primary) outcomes (>50%). Studies were classified as non-industry, 
industry-supported or industry-sponsored trials. For non-industry trials, no 
associations with pharmaceutical companies were reported in the manuscript. 
Studies reporting donation of study medication or placebos by a manufacturer, 
studies stating receipt of financial support from a pharmaceutical company and 
studies with authors affiliated to industry were classified as industry-supported 
trials. For industry-sponsored trials, a pharmaceutical company was explicitly 
described as the study sponsor, or the company funding the trial was reported 
to have participated in the study design, data collection, analysis, preparation 
of the manuscript, and/or the decision to publish. When doubt remained 
over sponsorship, information in the trial registry took precedence over other 
information (if registered).
Statistical analysis 
The association between publication and trial results and other characteristics 
was first analyzed using univariate logistic regression. Associations between 
acceptance (versus rejection) and trial characteristics were estimated with odds 
ratios (ORs) and 95% CIs. P-values were not adjusted for multiple comparisons and 
P<.05 was considered statistically significant. To control for several characteristics 
simultaneously, multiple logistic regression was used and ORs were calculated. As 
98 submitted manuscripts were accepted in this study, nine predictors could be 
entered in the model simultaneously, with ten acceptances per predictor. Besides 
the primary analysis (accepted vs all rejected manuscripts), two additional 
multivariable analyses were performed to compare accepted manuscripts with 
those outright rejected or rejected after peer review. These sensitivity analyses 
were conducted to assess whether the effects of the covariates were dependent 
on the type of rejection, i.e. whether the decision to reject manuscripts after initial 
editorial screening versus after peer review was of influence on the association 
between positive results and acceptance. Statistical analyses were performed 
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Figure 1. Publication status of manuscripts submitted to eight medical journals during the study time 
frame.
using SPSS software (version 20; Chicago, Illinois). 
Ethics
To assure confidentiality of information in manuscripts and submission systems, 
the authors signed confidentiality agreements before gaining access to the data. 
As standard editorial processes were unchanged, authors and peer reviewers were 
not informed about this study. Approval from a research ethics committee was not 
required, as this study involved no human participants.
Results
From January 2010 through April 2012, 15,972 manuscripts reporting original 
research were submitted to eight journals, of which 472 (3.0%) met all inclusion 
criteria. Ninety-eight manuscripts (20.8%) were published, 221 (46.8%) were 
outright rejected and 152 (32.2%) were rejected after peer review. One manuscript 
(0.2%) was withdrawn by authors before editorial decisions were made (Figure 1).
Original research manuscripts submitted  
(n=15,972) 
Manuscripts on drug RCTs submitted  
(n=472; 100%) 
Manuscripts not reporting 
results of drug RCTs  
(n=15,500; 97% of total) 
Rejected 
(n=373; 79%) 
Accepted for publication 
(n=98; 20.8%) 
Manuscript withdrawn by 
authors  
(n=1; 0.2%) 
Outright rejected  
(n=221; 46.8%) 
Rejected after peer review 
(n=152; 32.2%) 
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Table 3. Characteristics of submitted manuscripts and their association with publication: 
univariate analysis (accepted vs all rejected)
Total 
number 
(%*)
Published 
number (%§)
Odds ratio (95% CI) P-value
Total manuscripts 472 (100) 98 (20.8)
Results .909
Positive results 287 (60.8) 60 (20.9) 1.03 (0.65-1.62)
Negative results 185 (39.2) 38 (20.5) 1.00
Journal (IF) .000
BMJ (14.093) 94 (19.9) 14 (14.9) 1.00
Ann Rheum Dis (8.727) 56 (11.9) 33 (58.9) 8.10 (3.72-17.64)
Brit J Ophthalmol (2.902) 22 (4.7) 4 (18.2) 1.25 (0.37-4.26)
Diabetologia (6.814) 135 (28.6) 16 (11.9) 0.76 (0.35-1.64)
Gut (10.111) 61 (12.9) 11 (18.0) 1.24 (0.52-2.95)
Heart (4.223) 24 (5.1) 3 (12.5) 0.81 (0.21-3.07)
J Hepatol (9.264) 44 (9.3) 13 (29.5) 2.37 (1.00-5.60)
Thorax (6.840) 36 (7.6) 4 (11.1) 0.71 (0.22-2.31)
Journal type .130
General medical journal 94 (19.9) 14 (14.9) 0.62 (0.33-1.15)
Specialty journal 378 (80.1) 84 (22.2) 1.00
Sponsorship .000
Industry-sponsored 110 (23.3) 44 (40.0) 4.59 (2.64-8.00)
Industry-supported 149 (31.6) 27 (18.1) 1.54 (0.86-2.75)
Non-industry 213 (45.1) 27 (12.7) 1.00
Industry involvement .000
Industry-supported or 
sponsored
259 (54.9) 71 (27.4) 2.62 (1.61-4.26)
Non-industry 213 (45.1) 27 (12.7) 1.00
Trial registration .010
Yes 374 (79.2) 87 (23.3) 2.41 (1.23-4.71)
No 98 (20.8) 11 (11.2) 1.00
Sample size .000
>100 participants 211 (44.7) 60 (28.4) 2.35 (1.49-3.70)
≤100 participants 261 (55.3) 38 (14.6) 1.00
Number of centres .000
Multicentre 224 (47.5) 70 (31.2) 3.60 (2.22-5.84)
Single centre 248 (52.5) 28 (11.3) 1.00
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Study type .022
Posthoc/subgroup analysis 
RCT
72 (15.3) 15 (20.8) 1.11 (0.60-2.07)
Follow-up study of RCT 19 (4.0) 9 (47.4) 3.73 (1.47-9.52)
RCT 381 (80.7) 74 (19.4) 1.00
Authors’ country of 
residence
.003
Europe 224 (47.5) 57 (25.4) 2.42 (1.41-4.15)
US 71 (15.0) 19 (26.8) 2.57 (1.29-5.13)
Rest of the world 177 (37.5) 22 (12.4) 1.00
Journal impact factor 1.02 (0.95-1.09) .637
* Percentage of grand total of submitted manuscripts. § Percentage of row category that were accepted 
for publication. IF=journal impact factor, 2011.
Among 472 drug RCTs, 287 (60.8%) had positive results and 185 (39.2%) had 
negative results (Table 1). Of these, 135 (47.0%) and 86 (46.5%), respectively, were 
rejected immediately, and 91 (31.7%) and 61 (33.0%) after peer review. In total, 
compared to the number of submitted manuscripts, 60 (20.9%) positive studies 
were published compared to 38 (20.5%) negative studies. Publication outcomes 
of manuscripts submitted to each individual journal are shown in Table 1. For all 
journals except Thorax, the proportion of submitted manuscripts with positive 
results outnumbered those with negative results. In the BMJ, British Journal of 
Ophthalmology, Diabetologia, Gut, Heart, and Journal of Hepatology, a higher 
proportion of submitted manuscripts with negative results were published, while 
in Annals of the Rheumatic Diseases and Thorax a higher proportion of positive 
studies were published.
 
Submitted manuscripts reporting non-industry trials (n=213) had positive results 
in 138 manuscripts (64.8%), compared to 71 manuscripts (47.7%) on industry-
supported trials (n=149), and 78 manuscripts (70.9%) on industry-sponsored 
trials (n=110) (Table 2). When all trials with industry involvement (n=259) were 
taken together, 149 submitted manuscripts (57.5%) reported positive results. 
Twenty-seven (12.7%) non-industry trials were published, compared to 27 (18.1%) 
industry-supported trials, and 44 (40.0%) industry-sponsored trials.
In the univariate analysis, manuscripts reporting positive results were not more 
likely to be published compared to those with negative results (OR, 1.03; 95% CI, 
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0.65-1.62) (Table 3). Sponsorship was significantly associated with publication; 
industry-sponsored trials were more likely to be published than non-industry trials 
(OR, 4.59; 95% CI 2.64-8.00). Trial registration, sample size, being a multicentre trial 
or follow-up study of an RCT, a corresponding author from Europe or the US, and 
the journal to which manuscripts are submitted were associated with the chance 
of publication (Table 3).
In the multivariable analysis, accepted versus rejected manuscripts were 
compared after controlling for characteristics that were significantly associated 
with publication in the univariate analysis, or otherwise deemed important in 
relation to publication (Table 4). After adjustment for these variables, acceptance 
rates were not higher for trials with positive results than for trials with negative 
results (OR, 1.00; 95% CI, 0.61-1.66). The association of other factors with 
publication is shown in Table 4. In the multivariable analysis, industry-sponsorship 
and trial registration were no longer significantly associated with publication, 
while journal impact factor and submission to specialty journals were associated 
with an increased chance of acceptance. In the multivariable analyses comparing 
accepted manuscripts with those outright rejected or rejected after peer review, 
positive studies were not more likely to be published (Table 4). Findings of these 
analyses confirmed the primary analysis, as the direction of effects found was 
equal in all analyses. However, most associations were not statistically significant 
when comparing accepted manuscripts with those rejected after peer review.
Discussion
This is the first study that evaluated publication bias of manuscripts submitted 
to both a general medical journal and multiple specialty journals. Submitted 
manuscripts on drug RCTs were not more likely to be published if they reported 
positive results, regardless of whether rejected manuscripts were peer reviewed 
or not. This confirms findings of previous studies that followed manuscripts 
submitted to journals.[11-14] The proportion of submitted manuscripts with 
positive results outnumbered those with negative results, suggesting that 
publication bias mainly occurs prior to submission. This corresponds to findings 
of surveys among investigators on reasons for non-publication of results showing 
that studies primarily remained unpublished due to investigator-related factors.
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[25,26]
Both submitted non-industry and industry-sponsored trials were more likely to 
report positive results, in contrast to study findings indicating that particularly 
industry sponsorship is associated with favourable outcomes.[5,6] Interestingly, 
industry-sponsorship was associated with publication in the univariate analysis, 
as was previously found by Lynch et al.[13] This could be related to editorial 
decisions, as incentives such as citation rates [19,20] and reprint revenue [21,22] 
could favour the acceptance of these studies. Trial registration resulted in an 
increased unadjusted OR for publication, which may reflect that included journals 
adhere to ICMJE policy requiring registration as a condition of consideration for 
publication. Multicentre trials and studies enrolling more than 100 participants 
were more likely to be published, which was in agreement with findings of previous 
studies.[11,12] 
Previous studies found that manuscripts whose corresponding author was from the 
same country as the publishing journal were more likely to be accepted.[12,13,27] 
We included European journals only and found that having a corresponding 
author from either Europe or the US increased the chance of publication. This may 
result from a ‘familiarity effect’, leading reviewers and editors to be more accepting 
of trials with familiar interventions, clinical relevance, and language use.[13,28] 
After adjustment for other trial characteristics, submission to specialty journals was 
associated with publication. This seems plausible, as acceptance rates of general 
medical journals are known to be lower than those of specialty journals. A higher 
journal impact factor increased the chance of publication, though high impact 
journals generally have low acceptance rates. The direction of this association 
may be explained by relatively high acceptance rates found for two journals 
(Annals of the Rheumatic Diseases, Journal of Hepatology). Studies with negative 
results submitted to Annals of the Rheumatic Diseases and Thorax seemed less 
likely to be published. In view of the fact that BMJ was the only general medical 
journal that was included in this study and the number of accepted manuscripts 
per journal was relatively low, these data need to be interpreted with caution. 
The retrospective design of this study overcomes limitations that prospective 
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studies on publication bias in editorial decision making have. To study publication 
bias after manuscript submission, collaboration from editors is essential. In 
prospective studies, the decision-making behaviour of editors may be influenced 
by awareness of an ongoing investigation [11], introducing bias into the selection 
of manuscripts that are published. However, due to this retrospective design, 
our study time frame was limited by the retrospective availability of data in 
manuscripts submission systems. 
We included a general medical journal and specialty journals across different 
medical specialties, which increases the generalizability of our results compared 
to studies that only included large general medical journals or an orthopaedic 
journal.[11-14] However, we acknowledge that the journals included in our study 
are merely a sample of all peer reviewed medical journals. It might be that those 
journals that agreed to participate, did so based on existing editorial policy to 
publish papers of scientific worth regardless of the direction of results. As both 
BMJ and 5 of the 7 included specialty journals are published by the BMJ Group, 
the results of this study may have been affected by clustering effects based on 
publisher policy. Furthermore, investigators may prefer to submit large, multi-
centre, well-conducted studies to high impact journals like those included in our 
study. If publication bias is more likely to affect smaller studies, the inclusion of 
lower impact journals that more commonly receive smaller, single-center or 
negative studies might have influenced our results. However, no study has found 
evidence for publication bias in editorial decision making, irrespective of its design 
or included journals.
Other strengths include the objective selection criteria for journals and 
manuscripts, analysis of confounding characteristics, and classification of results 
and sponsorship based on predefined criteria.[24] Assessment of results and 
establishing the role of the funding source may appear to be straightforward, 
but in most studies on publication bias, methods for classification of results 
and sponsorship are only reported to a limited extent and definitions used are 
inconsistent across studies.[24]
This study has certain limitations. During the assessment of results and other 
characteristics, there was no blinding for publication status. In a retrospective 
88
Chapter 4
study, blinding for publication status would require editors to redact information 
made available to investigators, which could introduce substantial bias. 
Furthermore, the screening and selection of manuscripts and the extraction 
of manuscript characteristics were performed by one author, while this would 
ideally have been done by two independent assessors. We have focused on drug 
RCTs, and our results may not be generalizable to studies with different designs 
or interventions. The number of submitted drug RCTs varied between journals. 
This could be related to medical specialty and journal impact factor, but may also 
vary due to differences in retrospective availability of data in submission systems 
of journals. However, the proportion of drug RCTs among submitted manuscripts 
was comparable for all journals. We included European journals only, and editorial 
processes might slightly differ compared to US journals. Our study included a 
representative sample of drug RCTs though, as more than half of all submitted 
trials were from outside Europe.
In this study, we evaluated the overall editorial process after manuscript 
submission and have not specifically examined the role of peer reviewers in 
publication bias. Abbot and Ernst tested whether publication bias was present 
during peer review, and found that reviewers were no more likely to recommend 
publication of a fictitious manuscript with positive results.[29] However, Emerson 
et al. showed that a fabricated manuscript reporting positive results was more 
often recommended for publication than an otherwise identical manuscript 
reporting no effect.[10] It is difficult to assess the extent to which editors’ decisions 
were reliant on reviewers’ comments in this study. Kravitz et al. found that editors 
tend to place considerable weight on reviewers’ recommendations.[30] 
Finally, we have not determined quality scores for included trials. Lee et al. found 
an increased chance of acceptance for manuscripts with high quality scores.[12] 
The fact that multicentre and large (>100 participants) trials were more likely to 
be published can be seen as a proxy for quality. However, Lynch et al. found no 
relation between quality scores and publication.[13] Though observed acceptance 
rates did not favour manuscripts with positive results in our study, negative 
studies may have been of higher quality than positive studies, as was found by 
Lynch et al.[13] This could result from authors believing that negative papers are 
less likely to be accepted, therefore only submitting those of high quality. As a 
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consequence, submitted negative manuscripts may be of higher quality than 
positive manuscripts. Editorial bias occurs if submitted negative studies, although 
superior in quality, are not more likely to be published.[31] However, we found no 
differences between positive and negative manuscripts regarding sample size and 
multicentre status.
To reduce potential publication bias after submission, editors and peer reviewers 
could be blinded to results and discussion sections of manuscripts.[9,32,33] 
Preliminary decisions would be based on review of introduction and methods 
sections, and if manuscripts pass this initial stage, the full article could be 
provided to make a final evaluation. An RCT in which submitted manuscripts are 
randomized to either traditional review or review with initial blinding to results 
could confirm whether editors are not more likely to accept positive studies. 
However, no journals have implemented this two-stage review so far.
In conclusion, we found that for the sample of selected journals, there was no 
tendency to preferably publish submitted manuscripts on drug RCTs that reported 
positive results. The proportion of submitted manuscripts with positive results 
outnumbered those with negative results irrespective of sponsor type, suggesting 
that publication bias may occur mainly before manuscripts are submitted to 
journals.
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Abstract
Objective: To assess whether journals are more likely to reject manuscripts 
with differences between information in registries and articles. We compared 
differences by sponsorship and assessed whether selective reporting favored 
publication of significant outcomes.
Study design and setting: Drug trials submitted to eight journals (January 
2010-April 2012) were included. Publication status, primary outcomes, enrollment, 
and sponsorship were extracted. Primary outcomes and enrollment in registries 
and registration timing were reviewed. Prospective registration included 
registration before study start. Consistency between registered and reported 
information was evaluated.
Results: For 226 submitted manuscripts, primary outcomes were specified in 
both article and registry. 66/226 (29.2%) had primary outcome differences; 14/66 
manuscripts with differences (21.2%) and 46/160 without differences (28.8%) 
were accepted. 50 manuscripts (22.4%) had sample size differences; 10/50 with 
differences (20.0%) and 49/173 without differences (28.3%) were accepted. 
Industry-sponsored trials had less differences and were more often prospectively 
registered. After adjustment for sponsorship, differences and/or retrospective 
registration were not associated with decreased chance of acceptance (OR, 0.56; 
95% CI, 0.27-1.13). Primary outcome differences favored significant outcomes in 
49% of manuscripts.
Conclusion: Differences between registered and reported information are not 
decisive for rejection. Editors should assess consistency between registries and 
articles to address selective reporting.
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Introduction
Registration of clinical trials in public trial registries prior to patient enrollment 
has been introduced to increase transparency and accountability in the trial 
process and to address selective publication of study results.[1,2] Through trial 
registration, investigators should be able to identify all existing trials, whether 
published or not, and perform unbiased assessments of the available evidence for 
a medical intervention. The International Committee of Medical Journal Editors 
(ICMJE) enforced such registration in 2005 as a condition for publication of trial 
reports in their journals.[2] Several other medical journals have since adopted 
similar policies.[3-6] 
Although trial registration is now widely implemented, selective outcome reporting 
remains to be prevalent among adequately registered trials.[7] For a substantial 
proportion of randomized controlled trials (RCTs) published in high impact factor 
journals, evidence of differences between primary outcomes in trial registries 
and peer-reviewed publications has been found.[8-11] The differences favored 
publication of statistically significant outcomes in several trials.[8,9] Differences 
have also been detected between registered and published secondary outcomes, 
eligibility criteria, and sample sizes.[11-13] 
These findings suggest that registered trial information is not sufficiently being 
considered during manuscript review by journals to identify changes to trial 
characteristics. Cross-checking of information in registries with data actually 
reported in articles, during initial editorial screening or peer review, could 
improve the quality of the publication process. A limited number of studies 
have evaluated the role of registered information in editorial processes. Wager 
et al. showed that only 55 of a sample of 200 journals publishing clinical trials 
required trial registration according to their instructions to authors [14], which 
was comparable to findings of studies with smaller samples of journals.[3,5,6] 
A survey among peer reviewers of clinical trials indicated that only one-third of 
the reviewers surveyed examined registered information.[15] However, it has not 
been investigated whether journals requiring registration are less likely to publish 
trials with unacknowledged differences between information in registries and 
submitted manuscripts.   
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Previously, we reported on publication bias in editorial decision making by 
evaluating the publication status of 472 drug trials submitted to eight medical 
journals in relation to the direction of results and sponsorship.[16] The aim of 
this study was to assess whether editors are more likely to reject submitted 
manuscripts at initial editorial screening or after peer review if there are differences 
between registered and reported information on the primary outcome or sample 
size, using the same set of manuscripts. In addition, the extent of differences 
between registries and manuscripts was compared by sponsor type and we 
assessed whether selective outcome reporting favored publication of statistically 
significant outcomes.
Methods
Selection of journals and submitted manuscripts 
Six major general medical journals were asked to provide access to submitted 
manuscripts and decisions on publication. BMJ agreed to participate and the BMJ 
Group also provided access to data of BMJ specialty journals. In addition, other 
European specialty journals were asked to participate. All journals were selected 
based on 1. impact factor ( journals indexed with the highest impact factors within 
subject categories, according to the Institute for Scientific Information Journal 
Citation Report 2011); and 2. the number of drug RCTs published in 2010–2011. As a 
result, manuscripts submitted to one general medical journal (BMJ, impact factor 
2011 14.093) and seven specialty journals (Annals of the Rheumatic Diseases, 
8.727; British Journal of Ophthalmology, 2.902; Gut, 10.111; Heart, 4.223; Thorax, 
6.840 (all from the BMJ Group); Diabetologia, 6.814; and Journal of Hepatology, 
9.264) were included. We selected manuscripts on RCTs submitted from January 
2010–April 2012, if at least one study arm assessed the efficacy or safety of a drug 
intervention and a statistical test was used to evaluate treatment effects. This 
cohort of manuscripts has been described in detail previously.[16] In this study, 
post-hoc and subgroup analyses of RCTs, follow-up studies of RCTs, and articles 
reporting results of >1 trial were excluded because these are not routinely and/or 
separately registered. 
Data extraction manuscripts
The primary outcome was acceptance for publication. Full texts of submitted 
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manuscripts and publication status were retrieved from manuscript submission 
systems or provided by journals. Manuscripts were either outright rejected, 
rejected after peer review, or accepted for publication. For each manuscript, we 
reviewed the number of participants and the number and nature of reported 
primary outcomes. Primary outcomes were those explicitly reported as such in 
the article. If none was reported, we used the outcome stated in the sample size 
calculation. If none was identified in the text or sample size calculation, the article 
was considered to have no primary outcome reported. Information on sponsorship 
was previously extracted from manuscripts and classified according to predefined 
criteria.[17] In short, trials were classified as non-industry, industry-supported, or 
industry-sponsored. For non-industry trials, no associations with pharmaceutical 
companies were reported. Studies reporting donation of study medication by a 
manufacturer, studies stating receipt of financial support from a pharmaceutical 
company, and studies with industry-affiliated authors were classified as industry-
supported trials. For industry-sponsored trials, a pharmaceutical company was 
explicitly described as study sponsor, or the company funding the trial participated 
in the design, data collection, analysis, and/or preparation of the manuscript.[17] 
Assessment of trial registration
For each manuscript, we assessed trial registration according to ICMJE 
requirements.[18] We checked whether authors reported registering their trial 
and whether a registration number was included in the article or submission 
system. When no registration number could be identified, the trial was considered 
not registered. All journals included in this study required trial registration in 
their instructions to authors. Journals published by the BMJ Group explicitly 
required that trials were prospectively registered, while Diabetologia and Journal 
of Hepatology both referred to ICMJE policy on registration [18], in which trial 
registration at or before the time of first patient enrollment is required.
Data extraction trial registers
For each registered trial, we reviewed the anticipated sample size and the number 
and nature of primary outcomes in the registry. Primary outcomes were outcomes 
explicitly reported as such in the registry. If none was identified, the primary 
outcome was considered not registered. To take into account any amendments 
after initial trial registration [19], when feasible, we checked changes to the 
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protocol that were available using the history function (e.g., “History of Changes” 
on ClinicalTrials.gov archive site). For each trial, the registration date, start date and 
completion date reported in the registry were extracted. Trials were considered to 
be prospectively registered when they were registered prior to or at the reported 
start date of the study. As ClinicalTrials.gov only displays a month and year for 
start and completion dates, trials that were registered in the same month and year 
as the study start date were classified as prospectively registered. Trials registered 
after the start date (either before or after study completion) were classified as 
retrospectively registered. When it was unclear whether a trial was registered prior 
to the start of the study (i.e. start and/or end date missing in registry), trials were 
considered to be retrospectively registered. If trials were registered in multiple 
registries, we extracted data from the registry in which trial information was most 
completely reported. 
Definition of differences between registered and reported 
information
For manuscripts with primary outcomes specified in both the registry and the 
article (Sample 1), we assessed the consistency between registered and reported 
primary outcomes and sample sizes. As in previous studies, we defined differences 
in primary outcomes according to a modified classification of Chan et al. [8,9,20]:
1. The registered primary outcome was defined as a non-primary outcome in 
the submitted article.
2. The registered primary outcome was omitted in the submitted article.
3. A new primary outcome was introduced in the submitted article (i.e., an 
outcome that does not appear in the registry is introduced as primary in the 
article).
4. The primary outcome in the submitted article was described as a secondary 
outcome in the registry.
5. The timing of assessment of the registered primary outcome and that 
reported in the submitted article was different.
If the registry contained multiple primary outcomes, this definition was applied for 
each primary outcome. If the sample size reported in the manuscript was smaller 
than 75% of the anticipated sample size specified in the registry, we scored it as 
a difference. 
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Definition of selective outcome reporting
To determine whether selective outcome reporting favored publication of 
significant outcomes, trials registered before completion were selected (Sample 
2). For trials registered after completion, it was not possible to evaluate the risk 
of outcome reporting bias. P-values were extracted from manuscripts for all 
registered primary outcomes and for all outcomes reported in the article. P<.05 
was considered statistically significant. A difference was considered to favor 
statistically significant outcomes if [20]:
1. A new significant primary outcome supporting the efficacy of the test drug 
was introduced.
2. A non-significant primary outcome was omitted or defined as non-primary in 
the article.
3. A new efficacy primary outcome was introduced for a non-inferiority trial and 
treatments were equivalent.
If a non-significant safety primary outcome (i.e. the experimental drug had no 
more adverse effects than the comparator) was reported as non-primary in the 
article, this was not considered as a difference favoring significant outcomes. If 
the article contained no data for registered primary outcomes, the influence of 
differences could not be assessed. 
Statistical analysis
Descriptive statistics were used to describe included manuscripts (data presented 
as frequencies and percentages). We used correlation and regression analyses 
(univariate and multivariable) to test the relation between manuscript rejection 
and differences between registered and reported trial information. First, the 
association between publication status and differences between registered and 
reported data and timing of registration was analyzed using Pearson chi-square 
tests, adjusted for sponsorship. Subsequently, the probability of publication was 
evaluated with logistic regression. As the sample of manuscripts with primary 
outcomes in both the registry and the article was relatively small (n=226), of which 
60 were published, the number of parameters that could be included in the logistic 
model was limited. The effects of the three parameters on acceptance status 
were similar, therefore they were combined in the composite variable ‘difference 
between registered and reported information (primary outcome or sample 
size) and/or retrospective registration’ in the regression model. We estimated 
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associations between acceptance (versus rejection) and trial characteristics with 
odds ratios (ORs) and 95% confidence intervals (CIs). To control for sponsor type, 
multivariable logistic regression was used and ORs were calculated. Interaction 
of the composite variable and sponsorship was evaluated. P<.05 was considered 
statistically significant. Statistical analyses were performed using SPSS software 
(version 20; Chicago, Illinois). 
Results
Of the 472 manuscripts on drug RCTs submitted from January 2010 through April 
2012, 369 met all inclusion criteria (Figure 1). Of these, 73 (19.8%) were submitted 
to BMJ, 36 (9.8%) to Annals of the Rheumatic Diseases, 19 (5.1%) to British Journals 
of Ophthalmology, 93 (25.2%) to Diabetologia, 59 (16.0%) to Gut, 21 (5.7%) to 
Heart, 37 (10.0%) to Journal of Hepatology, and 31 (8.4%) to Thorax. Of the 369 
manuscripts, 269 (72.9%) were registered and for 226 (61.2%) a primary outcome 
was reported in both the article and the registry (Sample 1). Of these 226 trials, 186 
(82.3%) were registered before trial completion (Sample 2).
Of the 269 registered trials, most were registered at ClinicalTrials.gov (n=178, 
66.2%), followed by International Standard Randomized Controlled Trial Number 
Register (ISRCTN) (n=27, 10.0%), Australian New Zealand Clinical Trials Registry 
(ANZCTR) (n=16, 5.9%), and EU Clinical Trials Register (EU-CTR) (n=16, 5.9%) (Table 
1). Most trials were registered before trial start (n=107, 39.8%) or after the start date 
but before trial completion (n=110, 40.9%). However, 40 (14.9%) were registered 
after completion and timing of registration was unknown for 12 (4.5%) trials. One 
primary outcome was reported in the registry for 181 (67.3%) trials, while 8 (3.0%) 
reported no primary outcome, 51 (19.0%) had two primary outcomes, and 29 
(10.8%) had three to nine primary outcomes. The number of primary outcomes 
reported in articles varied from 0 to seven, with most trials (n=188, 69.9%) reporting 
one primary outcome. 
Of the 226 manuscripts with primary outcomes in both the registry and the 
article (Sample 1), 66 (29.2%) had differences between registered and reported 
primary outcomes, while 160 (70.8%) did not (Table 2). Of these, 30 (45.5%) and 
60 (37.5%), respectively, were outright rejected. Twenty two (33.3%) manuscripts 
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Figure 1. Flowchart of trial registration and sample selection.
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472 Submitted manuscripts on drug RCTs  
369 Manuscripts meeting all inclusion criteria  
103 Manuscripts excluded  
77 Post-hoc or subgroup analyses of RCTs  
19 Follow-up studies of RCTs  
7 Reporting results of >1 study  
269 Manuscripts registered  
100 Manuscripts excluded  
91 No registration number in article  
5 Registration number in article, not traceable in registry  
3 Registration number in article, registry describing     
   other trial 
1 Registry in article, number not mentioned  
 
SAMPLE 1:  
226 Manuscripts with primary outcomes 
included in analysis of registered vs reported 
data and editorial decision making  
43 Manuscripts excluded  
43 No primary outcome specified in registry and/or article  
 
40 Manuscripts excluded  
30 Registered a er completion  
10 Time of registration unknown  
SAMPLE 2:  
186 Manuscripts registered before completion 
included in analysis of selective outcome 
reporting  
 
Figure 1.  Flowchart of trial registration and sample selection
 
 
 
 
 
 
 
with primary outcome differences were rejected after peer review, compared to 
54 (33.8%) without differences. Eventually, 14 (21.2%) manuscripts with primary 
outcome differences and 46 (28.8%) without differences were accepted. Overall, 
the pattern of editorial decisions was not significantly different for manuscripts 
with or without changed primary outcomes (p=0.418). Differences between 
registered and reported sample sizes (i.e. sample size in the manuscript smaller 
than 75% of the anticipated enrolment specified in the registry) were found for 50 
(22.4%) manuscripts, while 173 (77.6%) had no differences (Table 2). Of these, 19 
(38.0%) and 71 (41.0%), respectively, were outright rejected. Twenty one (42.0%) 
manuscripts with sample size differences were rejected after review, compared 
to 53 (30.6%) without differences. Ten (20.0%) manuscripts with sample size 
differences and 49 (28.3%) without differences were published. Overall publication 
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Table 1. Registration characteristics of manuscripts submitted to eight medical journals 
(n=269)
Registered manuscripts, n (%)
Total manuscripts 269 (100)
Sponsor type 
Non-industry 114 (42.4)
Industry-supported 85 (31.6)
Industry-sponsored 70 (26.0)
Trial registry
ClinicalTrials.gov 178 (66.2)
ISRCTN 27 (10.0)
ANZCTR 16 (5.9)
EU-CTR 16 (5.9)
Other 32 (11.9)
Timing of registration
Before start of trial 107 (39.8)
Before end of trial, after start date 110 (40.9)
After end of trial 40 (14.9)
Unknown (no dates in registry) 12 (4.5)
Number of primary outcomes registered
0 8 (3.0)
1 181 (67.3)
2 51 (19.0)
3 to 9 29 (10.8)
Number of primary outcomes in article
0 36 (13.4)
1 188 (69.9)
2 34 (12.6)
3 to 7 11 (4.1)
ISRCTN=International Standard Randomized Controlled Trial Number Register; ANZCTR=Australian 
New Zealand Clinical Trials Registry; EU-CTR=EU Clinical Trials Register. 
status was not significantly different based on sample sizes differences (p=0.271).
For 132 (58.4%) of 226 manuscripts, timing of registration was retrospective (i.e. after 
trial start date) or unknown, while 94 (41.6%) were prospectively registered (Table 
2). Of these, 59 (44.7%) and 31 (33.0%), respectively, were outright rejected. Forty 
three (32.6%) retrospectively registered trials were rejected after review, compared 
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to 33 (35.1%) trials prospectively registered. Eventually, 30 (22.7%) retrospectively 
and 30 (31.9%) prospectively registered manuscripts were accepted. Overall 
publication status did not significantly differ by timing of registration (p=0.154). 
With regard to the composite variable (‘difference between registered and 
reported information and/or retrospective registration’), 175 (77.4%) trials had a 
discrepancy and/or were retrospectively registered, while 51 (22.6%) did not (Table 
2). Of these, 75 (42.9%) and 15 (29.4%), respectively, were outright rejected. Sixty 
one (34.9%) manuscripts with differences and/or retrospective registration were 
rejected after review, compared to 15 (29.4%) prospectively registered without 
differences; 39 (22.3%) and 21 (41.2%) manuscripts were eventually accepted, 
respectively. The overall publication status was significantly associated with the 
composite variable (p=0.024).
Of the non-industry trials (n=89), 31 (34.8%) had primary outcome differences, 
compared to 23 (31.5%) of the trials that were supported by industry (n=73), and 12 
(18.8%) of the industry-sponsored trials (n=64) (Table 2). Sample size differences 
were found for 19 (21.8%) non-industry trials, 22 (30.1%) industry-supported trials, 
and 9 (14.3%) industry-sponsored trials. Industry-sponsored trials were less often 
retrospectively registered (43.8%) than industry-supported (61.6%) and non-
industry-trials (66.3%).
In the univariate analysis, the effects found for primary outcome differences, 
sample size differences, and timing of registration were similar (Table 3). The 
composite variable ‘difference between registered and reported information and/
or retrospective registration’ was significantly associated with a decreased chance 
of acceptance (OR, 0.41; 95% CI, 0.21-0.79). After adjustment for sponsor type in 
the multivariable analysis, the composite variable was no longer significantly 
associated with publication, though the direction of the effect was equal to the 
univariate analysis (OR, 0.56; 95% CI, 0.27-1.13). There was no interaction of the 
composite variable and sponsor type (p=0.122).
Among 66 of 226 (29.2%) manuscripts for which primary outcome differences 
were detected, 21 articles had two reasons for a difference in primary outcomes 
(Table 4). Differences most often consisted of a registered primary outcome that 
was reported as a non-primary outcome in the article (34 of 226, 15.0%), followed 
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Table 3. Characteristics of registered manuscripts and their association with publication 
(accepted vs all rejected) (n=226)
Total 
n (%)
Published
n (%*)
OR (95% CI) 
Univariate 
Total manuscripts 226 (100) 60 (26.5)
Different primary outcome in registry and 
article 
No 160 (70.8) 46 (28.8) 1.00
Yes 66 (29.2) 14 (21.2) 0.67 (0.34-1.32)
Different sample size in registry and article¶
Sample size article ≥75% of registered sample size 173 (77.6) 49 (28.3) 1.00
Sample size article <75% of registered sample size 50 (22.4) 10 (20.0)
0.63 
(0.29-1.36)
Timing of registration
Prospective 94 (41.6) 30 (31.9) 1.00
Retrospective or unknown 132 (58.4) 30 (22.7) 0.63 (0.35-1.14)
Difference between registered and reported 
information and/or retrospective registration
No 51 (22.6) 21 (41.2) 1.00
Yes 175 (77.4) 39 (22.3) 0.41 (0.21-0.79)
Sponsor type
Non-industry 89 (39.4) 14 (15.7) 1.00
Industry-supported 73 (32.3) 14 (19.2) 1.27 (0.56-2.87)
Industry-sponsored 64 (28.3) 32 (50.0)
5.36 
(2.53-11.37)
OR (95% CI) 
Multivariable
Difference between registered and reported 
information and/or retrospective registration
No 1.00
Yes 0.56 (0.27-1.13)
Sponsor type
Non-industry 1.00
Industry-supported 1.26 (0.55-2.85)
Industry-sponsored
4.80 
(2.23-10.31)
* Percentage of row category that were accepted for publication. ¶ 3 manuscripts reported no sample 
size in the registry. ‘Sponsor type’ and ‘Difference between registered and reported information and/
or retrospective registration’ were included in the multivariable model. OR=odds ratio; CI=confidence 
interval.
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by introduction of a new primary outcome in the article (22 of 226, 9.7%). Among 
186 of 226 (82.3%) trials that were registered before completion (Sample 2), 49 
had primary outcome differences. Twenty four of 49 (49.0%) manuscripts had 
differences that favored statistically significant outcomes.
Discussion
In this study, we focused on the role of registered trial information in editorial 
decision making and investigated whether differences between trial characteristics 
specified in registries and those reported in submitted manuscripts were 
associated with the chance of subsequent publication. 
For almost 30% (66 of 226) of submitted manuscripts on drug RCTs, we found 
differences between primary outcomes in registries and articles. The chance 
of rejection after initial editorial screening or peer review was not substantially 
Table 4. Type of differences between registered and reported primary outcomes (n=226) and 
selective outcome reporting (n=186)
Registered 
manuscripts, n (%)
Total manuscripts 226 (100)
Different primary outcome in registry and article 66 (29.2)
Type of difference*
Registered primary outcome defined as non-primary outcome in article 34 (15.0)
Registered primary outcome omitted in article 14 (6.2)
New primary outcome introduced in article 22 (9.7)
Primary outcome in article described as secondary outcome in registry 12 (5.3)
Different timing of assessment of primary outcome  5 (2.2)
Total manuscripts registered before trial completion 186 (82.3)
Difference favoring statistically significant outcomes 49¶
Yes 24 (49.0)
No 15 (30.6)
Impossible to conclude 10 (20.4)
* 21 articles had 2 reasons for difference in primary outcome. Therefore, the total % of type of differences 
is >29.2%. ¶ Of 186 trials registered before completion, 49 had differences between registered and 
reported primary outcomes.
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different between trials with or without primary outcome differences. Eventually, 
21.2% of manuscripts with differences versus 28.8% of those without differences 
were accepted. Interestingly, the proportion of submitted manuscripts with 
primary outcome differences was comparable to that found in previous studies 
which included only published articles.[8,10,11,13] More than 20% (50 of 223) 
of the manuscripts reported sample sizes smaller than 75% of the enrolment 
specified in the registry. The influence of this difference on rejection rates after 
initial screening or peer review was modest. Acceptance rates for trials with and 
without sample size differences were 20.0% versus 28.3%, respectively. For almost 
60% (132 of 226) of the trials, timing of registration was retrospective or unknown. 
Publication status did not significantly differ by timing of registration and 22.7% of 
the retrospectively registered trials versus 31.9% of those registered prospectively 
were accepted. The univariate analysis indicated that the composite variable 
‘difference between registered and reported information and/or retrospective 
registration’ was associated with a decreased chance of publication, though this 
association was not significant after adjusting for sponsor type. 
Industry-sponsored trials less often had primary outcome and sample size 
differences than non-industry or industry-supported trials. This corresponds 
to findings of a recent study that examined trials submitted to a Dutch research 
ethics committee (REC) indicating that non-industry trials had significantly more 
problems in recruiting the required number of subjects than studies initiated 
by pharmaceutical companies.[21] Trials not including the required number of 
subjects may have lower chances of meeting the study objectives and subjects 
may be unnecessarily exposed to risks and burdens.[21,22] In contrast, we found 
that only 5.8% (13 of 223) of the manuscripts reported sample sizes larger than 
125% of the enrolment specified in the registry. 
For manuscripts that were registered before trial completion, we found that 
primary outcome differences favored statistically significant results in almost 50% 
(24 of 49) of the manuscripts. This number lies between the proportions reported 
in previous studies.[8,9] Our study sample was too small to determine whether 
selective outcome reporting in favor of  significant outcomes was associated with 
sponsor type.
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In agreement with previous studies, approximately a quarter of the trials were not 
registered.[8,9,13,23] Industry-sponsored and industry-supported trials were more 
often registered than non-industry trials. Both the timing and quality of registration 
should be improved, as only 40% of the trials was prospectively registered and 
primary outcomes or sample sizes were missing for several trials. Similar findings 
regarding the timing and accuracy of registration have previously been shown, and 
investigators have emphasized that without adequate registration, the potential 
to address selective publication is limited.[24-26]
This study is strengthened by the inclusion of submitted manuscripts, instead of 
only published articles.[8-13] By including both rejected and accepted articles, 
we were able to evaluate the role of registered information in editorial decision 
making. Furthermore, as we selected manuscripts submitted from 2010 to 2012, 
the number of trials that started enrolment before the implementation date of the 
ICMJE policy on prospective registration (i.e. July 1, 2005) was most likely lower 
than in previous studies including trials published in earlier years.[8-11]
This study has some limitations. We determined trial registration by checking 
whether authors reported registering their trial and included a registration 
number. We have not contacted authors or searched registries to identify trial 
records if no registration number was reported. We compared registered and 
reported primary outcomes and sample sizes, while differences may also be 
common for other trial characteristics including secondary outcomes, eligibility 
criteria, and trial interventions [10,11], and for results and adverse events reported 
in the ClinicalTrials.gov results database.[27,28] In addition, it could be argued that 
sample size and primary outcome differences are not completely comparable. 
Differences between registered and reported sample sizes may reflect problematic 
recruitment, and may not necessarily constitute a reporting quality issue as with 
changed primary outcomes. 
Furthermore, trial protocol amendments that occur during the course of a trial, 
after initial registration, may not always be accurately reported in the registry. 
This may in part explain the observed difference among industry-sponsored trials 
and those with other funding sources regarding the extent of differences between 
registered and reported information. Through better administrative support, 
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registered information may be more adequately updated for industry-sponsored 
trials in case of protocol amendments.[19]
Finally, although all journals required trial registration, there may be variation 
among journals in how strictly this policy is being enforced. Some journals may 
insist that registered information and the timing of registration are verified as part 
of an initial check of submitted articles, while others may do little to assess whether 
authors comply with requirements.[14] Overall, we found that rejection rates 
for manuscripts that were retrospectively registered or had primary outcome or 
sample size differences were not substantially increased, but it was not possible to 
assess for individual journals whether they actually only considered prospectively 
registered manuscripts without unacknowledged differences between registered 
and reported information. A survey among editors may provide more insight.
Although introduction of the ICMJE requirement of prospective trial registration in 
2005 led to a large increase in the number of trial registrations [29], our study and 
prior research indicate that editors and reviewers do not take full advantage of 
the possibilities provided by registration.[8,9,14,15] Though editors and reviewers 
who evaluated manuscripts included in this study had the opportunity to identify 
changes to trial characteristics and address selective outcome reporting, we 
found inconsistencies between registered and reported information among 
articles that were accepted for publication. The consistency between articles and 
registries should be routinely and thoroughly checked by journal staff to identify 
any changes. If necessary, editors should require explanations from authors which 
could be explicitly reported in published articles.
In conclusion, differences between trial information specified in registries and 
that reported in submitted manuscripts were not a decisive factor for rejection 
after initial editorial screening or after peer review. Editors should assess the 
consistency between registries and articles to address selective reporting and 
improve the quality of the publication process.  
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Abstract
Objective: During peer review, submitted manuscripts are scrutinized by 
independent experts to assist journal editors in their decision making and to 
help improve the quality of articles. In this retrospective cohort study, peer 
review comments for drug trials submitted to medical journals were analysed to 
investigate whether there is a relation between the content of these comments 
and sponsorship, direction of results, and decision about acceptance.
Design/setting: Descriptive content analysis of reviewer comments made on 
manuscripts on drug trials submitted to eight medical journals (January 2010-April 
2012). For each manuscript, the number of reviewers, decision about acceptance, 
sponsorship, and direction of results were extracted. Reviewer comments were 
classified using a predefined checklist. 
Results: Reviewer reports for 246 manuscripts were assessed. Industry-sponsored 
trials were more likely to receive comments about lack of novelty (8.9%) than 
industry-supported (2.5%) and non-industry trials (6.1%, overall p=0.038). Non-
industry trials more often received comments about poor experimental design 
(69.7%) than industry-supported (58.8%) and industry-sponsored trials (52.9%, 
overall p=0.019). Non-industry trials were also more likely to receive comments 
regarding inappropriate statistical analyses (28.4%) than industry-supported 
(23.5%) and industry-sponsored trials (15.1%, overall p=0.006). Manuscripts 
with negative results were more likely to receive comments about inappropriate 
conclusions (29.3%) than those with positive results (18.9%, p=0.010). Rejected 
manuscripts had more often received comments on the research question not 
being clinically relevant (7.8%) than accepted manuscripts (1.6%, p=0.002), and 
also on lack of novelty (8.3% vs 2.6%, p=0.008) and poor experimental design 
(68.6% vs 50.5%, p<0.001). 
Conclusions: Reviewers identified less shortcomings regarding design and 
statistical analyses in industry-related trials, but commented more often on lack 
of novelty in industry-sponsored trials. Negative trial results did not significantly 
influence the nature of comments other than appropriateness of the conclusion. 
Manuscript acceptance was primarily related to the research question and 
methodological robustness of studies.
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Introduction
At peer-reviewed medical journals, submitted articles are sent out for external 
peer review if they are considered to be potentially suitable for publication. During 
peer review, manuscripts are scrutinized by independent experts or peers in the 
same field, to assist editors in their decision making and to help improve the 
quality of submitted articles.[1, 2] The peer review process has been investigated 
to a limited extent. Some studies addressed the effects of blinding and training of 
reviewers, the detection rate of deliberately introduced errors by reviewers, and 
the impact of peer review on the quality of published articles.[3-8] 
Few studies have systematically analyzed the content of reviewer comments on 
submitted articles. Bordage studied the reasons given by reviewers for rejection 
of manuscripts submitted for publication in conference proceedings on research 
in medical education.[9] Inappropriate statistics and overinterpretation of results 
were commonly reported.[9] Turcotte et al. analyzed reviewer comments for 
manuscripts submitted to the Canadian Journal of Anesthesia, and found that 
lack of originality, inadequate experimental design, and inappropriate conclusions 
were the main determinants of an article’s fate.[10] Hopewell et al. focused on 
reviewer comments on the reporting of methodological items in randomised 
trials submitted to open peer review journals.[7] The type of changes requested 
by reviewers included addition or clarification of randomisation, blinding, and 
sample size, and toning down of conclusions to reflect the results.[7]
The content of reviewer comments may be related to the direction of results 
and sponsorship. Emerson et al. compared reviewer reports for a fabricated 
manuscript reporting positive results and an otherwise identical manuscript 
reporting no effect.[11] Reviewers detected more errors in the no-difference 
version and awarded higher scores to the methodology section of the positive 
manuscript, although the methods sections were identical.[11] Emerson et al. 
showed that the positive article was more often recommended for publication 
than the no-difference version [11], although this observation could not be 
confirmed by others.[12] None of the previous studies on peer review compared 
reviewer comments according to whether reported trials were sponsored by 
pharmaceutical companies or non-profit organisations.
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Analysis of reviewer comments provides more insight into the shortcomings of 
drug trials that are submitted to medical journals, both from the perspective of 
the design and conduct of trials and the reporting quality in articles. It would 
be interesting to determine whether the occurrence of specific shortcomings 
in manuscripts is affected by sponsorship and results being either positive or 
negative. In the current study, we performed a descriptive content analysis of 
peer review comments made on manuscripts on drug trials submitted to eight 
medical journals to investigate the relationship between the content of comments 
and sponsorship, direction of results, and decision about acceptance, using a 
previously reported cohort.[13] 
Methods
Journal and manuscript selection
We included manuscripts submitted from January 2010 through April 2012 to 
one general medical journal (BMJ) and seven specialty journals (Annals of the 
Rheumatic Diseases, British Journal of Ophthalmology, Gut, Heart, Thorax (all 
from the BMJ Group), Diabetologia, and Journal of Hepatology). We selected 
randomized controlled trials, in which at least one study arm assessed the efficacy 
or safety of a drug and a statistical test was used to evaluate treatment effects. 
This cohort has been described in detail previously.[13] This study was limited to 
manuscripts that were sent out for external peer review.
Data extraction manuscripts
For each manuscript, the decision about acceptance and reviewer reports were 
extracted from submission systems or provided by journals. Manuscripts were 
either rejected after review or accepted for publication. We determined the 
number of reviewers that evaluated the first submitted version of each article. 
Manuscripts could be evaluated during multiple rounds of review before a 
final decision was made, but we focused on comments that were made during 
initial peer review of articles. Reviews of revised manuscripts were excluded. 
Information on sponsorship and the direction of results was previously extracted 
from manuscripts and classified according to predefined criteria.[14] Reviewers 
were aware of the sponsorship of trials. In short, trials were classified as non-
industry, industry-supported or industry-sponsored trials. For non-industry trials, 
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no associations with pharmaceutical companies were reported. Studies reporting 
donation of study medication by a manufacturer, studies stating receipt of financial 
support from a pharmaceutical company, and studies with industry-affiliated 
authors were classified as industry-supported trials. For industry-sponsored 
trials, a pharmaceutical company was explicitly described as study sponsor, or 
the company funding the trial participated in the design, data collection, analysis, 
and/or preparation of the manuscript. Trial results were scored as positive if 
results reported for the primary endpoint were statistically significant (p<0.05 or 
95% confidence interval (CI) for difference excluding 0 or 95% CI for ratio excluding 
1) and supported the efficacy of the test drug, and negative if they did not. Results 
of non-inferiority trials were classified as positive if treatments were equivalent. 
Safety trials were classified as positive if the test drug was as safe as or safer than 
control. 
Classification of reviewer comments
A validated instrument for classification of reviewer comments does not exist. 
Included journals did not provide standardized forms to reviewers, but general 
guidance for peer review was available on each journals’ website. Based on this 
guidance [15-17] and previous research on peer review [9, 10, 18-20], a classification 
checklist for negative reviewer comments was composed. In two consecutive 
training sessions, reviewer comments for 10 randomly selected manuscripts were 
independently classified by two raters (MvL and HJO) in each session, to assess the 
consistency between raters and check on the comprehensiveness of the checklist. 
Both after the first and second training session, disparities in the interpretation 
of comments were discussed and the checklist was revised accordingly. The 
final version of the checklist (Supplemental Table 1) was then tested on reviewer 
comments for a random sample of 30 manuscripts, that were independently 
classified by the two raters. Assuming an inter-rater agreement of at least 80% for 
each type of comment with the final checklist, 30 manuscripts were sufficient to 
estimate the agreement with a precision (standard error) of at most 7%. If the inter-
rater agreement during this test was considered sufficiently high, a single reviewer 
(MvL) could continue with the rating process. After the classification of reviewer 
comments for these 30 manuscripts, we calculated the percentage of agreement 
between raters for each type of comment in the checklist. Kappa statistics were not 
considered suitable as some types of comments were rarely scored and resulting 
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kappa values would be inaccurate.[21] For these 30 manuscripts, classification 
discrepancies were resolved by consensus between raters if the agreement for a 
comment was <85%. For the other types of comments, the score assigned by the 
rater who subsequently classified all comments for the other manuscripts (MvL) 
was decisive. Overall, reviewer comments for 50 manuscripts were scored by two 
raters in this study, which was equivalent to 20% (50 of 246) of the total number 
of included manuscripts. For each manuscript, a reviewer could have several 
remarks related to one type of comment. However, each type of comment was 
scored maximally once per reviewer. 
Statistical analysis
Descriptive statistics were used to describe included manuscripts (data presented 
as frequencies and percentages). The relationship between each type of comment 
and sponsorship, direction of results, and decision about acceptance was 
analyzed using a generalized linear mixed model based on generalized estimating 
equations (GEE) with a binary distribution for the dependent variable and an 
identity link. In this model, the comment score of a reviewer (comment versus no 
comment) was used as the dependent variable. We included sponsor type, results, 
or decision about acceptance as fixed variable in the model, and – if possible (if 
the model converged) – journal, to control for the journal to which a manuscript 
was submitted. The unique identification number that manuscripts received from 
a journal was included as cluster variable (random effect). Most manuscripts were 
reviewed by several reviewers. The model estimates the percentage of reviewers 
that will comment on a manuscript, depending on sponsor type, results, or 
decision about acceptance (“mean percentage of comments on a manuscript”). If 
a lower limit of the resulting confidence interval was negative, it was truncated to 
zero. The number of different types of comments per manuscript was compared 
by sponsorship, results, or decision about acceptance using univariate analysis of 
variance. We controlled for the number of reviewers per manuscript by including 
this as a covariate in the model. Two-sided p<0.05 was considered statistically 
significant. P-values were not adjusted for multiple comparisons. Statistical 
analyses were performed using SPSS software (version 20) and SAS for Windows 
(version 9.2, SAS Institute Inc).
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Table 1. Characteristics of included manuscripts
Number of manuscripts (%)
Total 246 (100)
Journal
BMJ 39 (15.9)
Annals of the Rheumatic Diseases 44 (17.9)
British Journal of Ophthalmology 12 (4.9)
Gut 31 (12.6)
Heart 8 (3.3)
Thorax 23 (9.3)
Diabetologia 51 (20.7)
Journal of Hepatology 38 (15.4)
Decision about acceptance
Rejected after peer review 150 (61.0)
Accepted for publication 96 (39.0)
Sponsor type
Non-industry 89 (36.2)
Industry-supported 78 (31.7)
Industry-sponsored 79 (32.1)
Trial results
Positive results 150 (61.0)
Negative results 96 (39.0)
Number of reviewers per manuscript
1 10 (4.1)
2 160 (65.0)
3 61 (24.8)
4 13 (5.3)
5 2 (0.8)
Ethics
To assure confidentiality of manuscripts and reviewer reports, confidentiality 
agreements were signed by the authors before gaining access to the data. As 
standard editorial and peer review processes were unchanged, authors and 
reviewers were not informed about this study. Research ethics committee approval 
was not required as this study involved no human participants.
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Table 2. Distribution of reviewer comments - by sponsor type
Mean percentage of comments on a manuscript (95% CI)*
Type of comment
Non-industry 
(N=89)
Industry-
supported 
(N=78)
Industry-
sponsored 
(N=79)
P-value
Importance
1. Research question not 
clinically relevant
6.3 (2.4-10.2) 6.1 (2.2-10.1) 3.3 (0.3-6.3) 0.372
Originality
2. Lack of novelty 6.1 (2.6-9.7) 2.5 (0.1-4.9) 8.9 (4.1-13.7) 0.038
Background and rationale
3. Incorrect background 
information
20.4 (15.2-25.5) 18.4 (12.2-24.6) 18.8 (12.5-25.2) 0.877
4. Poor justification for 
conducting study
1.5 (0.0-3.1) 2.8 (0.4-5.1) 6.3 (2.4-10.1) 0.081
Methods
5. Poor experimental design 69.7 (63.1-76.3) 58.8 (50.2-67.4) 52.9 (43.9-61.9) 0.019
6. Methods inadequately 
reported
60.5 (53.9-67.1) 54.7 (46.7-62.7) 50.8 (42.4-59.2) 0.209
7. Statistical analysis 
methods inappropriate
28.4 (22.3-34.6) 23.5 (16.4-30.5) 15.1 (10.1-20.2) 0.006
Results
8. Study outcome data 
incomplete
65.9 (59.4-72.4) 68.0 (59.7-76.4) 58.7 (50.6-66.8) 0.215
9. Flow of participants 
through study unclear
7.7 (3.8-11.6) 7.8 (3.3-12.4) 4.6 (1.8-7.4) 0.323
Discussion and conclusion
10. Meaning results 
inadequately discussed
44.2 (36.6-51.9) 46.7 (38.5-54.9) 56.1 (47.5-64.7) 0.090
11. Study insufficiently 
related to literature
15.2 (10.4-20.0) 15.5 (8.3-22.6) 8.7 (4.2-13.3) 0.180
12. Limitations not 
sufficiently discussed
17.2 (11.6-22.8) 19.9 (14.7-25.1) 13.8 (8.3-19.3) 0.223
13. Conclusions 
inappropriate
24.2 (17.7-30.6) 23.0 (16.0-30.1) 20.0 (13.2-26.8) 0.652
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Abstract
14. Abstract does not 
correctly reflect paper
16.2 (11.5-20.9) 17.1 (11.8-22.4) 14.4 (8.8-19.9) 0.768
15. Discrepancies between 
abstract and main text
2.0 (0.1-3.9) 0.6 (0.0-1.6) 1.0 (0.0-2.5) 0.443
References
16. References missing/
irrelevant references used 
11.4 (7.0-15.8) 12.0 (6.6-17.4) 11.5 (6.1-16.8) 0.985
17. Errors in reference 
citation
1.5 (0.0-3.1) 1.7 (0.0-3.5) 4.6 (1.7-7.5) 0.159
Presentation
18. Title not representative 
of study
5.0 (1.7-8.2) 8.1 (3.3-12.8) 1.5 (0.0-3.1) 0.012
19. Poor writing 42.8 (35.5-50.2) 35.4 (27.9-42.9) 34.7 (26.8-42.6) 0.258
20. Inaccurate tables or 
figures
37.0 (30.9-43.1) 44.1 (36.5-51.7) 37.2 (29.5-45.0) 0.306
Ethics
21. Ethics committee 
approval not clear
2.0 (0.1-3.9) 1.7 (0.0-3.5) 2.1 (0.1-4.1) 0.951
22. Other ethical issues 
related to study
3.1 (0.0-6.3) 4.1 (0.7-7.5) 2.0 (0.1-4.0) 0.555
Trial registration, protocol, 
CONSORT
23. Registration/protocol/
CONSORT missing
2.5 (0.4-4.6) 2.8 (0.4-5.1) 2.6 (0.4-4.8) 0.984
24. Deviations from registry 
or protocol
1.4 (0.0-3.3) 1.8 (0.0-3.8) 1.7 (0.0-3.6) 0.961
Conflicts of interest (COI)
25. Bias by author COIs/
contribution funder unclear
2.5 (0.4-4.6) 2.3 (0.1-4.4) 3.6 (1.1-6.2) 0.707
26. Systematic bias or spin in 
favour of sponsor
0.0 (0.0-1.1) 0.5 (0.0-1.8) 1.7 (0.2-3.1) 0.139
* The mean percentage of comments on a manuscript is controlled for the journal to which a 
manuscript was submitted. N=number of submitted manuscripts; CI=confidence interval.
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Results
From January 2010 through April 2012, 472 manuscripts on drug RCTs were 
submitted to eight journals, of which 250 articles (53.0%) were externally reviewed. 
For 246 manuscripts, reviewer comments for authors were available. Of these 246, 
96 (39.0%) were accepted for publication (Table 1). Eighty-nine (36.2%) were non-
industry trials, while 78 (31.7%) were industry-supported and 79 (32.1%) were 
industry-sponsored trials. Most articles reported positive results (N=150, 61.0%). 
The number of reviewers for the first submitted version of an article ranged from 1 
to 5. In total, 575 reviewer reports were evaluated. 
Overall, the level of inter-rater agreement for the final version of the classification 
checklist was good. For all types of comments, the agreement between raters 
was close to or higher than 80%. For 20 of 26 items, there was >85% agreement 
(Supplemental Table 2).
Overall, the types of comments that were most frequently reported by reviewers 
included poor experimental design (range of point estimators in Table 2, 3, and 
4; 50.5-69.7%), inadequately reported methods (50.8-60.5%), incomplete study 
outcome data (58.7-68.2%), inadequate discussion of the meaning of results (44.2-
56.1%), poor writing (34.7-42.8%), and inaccurate tables or figures (35.1-44.1%). In 
Table 2, the mean percentage of comments on a manuscript is compared by sponsor 
type. For several types of comments, there was a relation between sponsorship 
and the mean percentage of comments. The percentage of comments regarding 
lack of novelty was significantly associated with sponsorship (p=0.038); industry-
sponsored trials were more likely to receive this comment (8.9%) than industry-
supported (2.5%) and non-industry trials (6.1%). The percentage of comments 
regarding poor experimental design was also associated with sponsorship 
(p=0.019); non-industry trials more often received this comment (69.7%) than 
industry-supported (58.8%) and industry-sponsored trials (52.9%). Furthermore, 
the percentage of comments about inappropriate statistical analysis methods 
was associated with sponsorship (p=0.006); non-industry trials were more likely 
to receive this comment (28.4%) than industry-supported (23.5%) and industry-
sponsored trials (15.1%). The percentage of comments regarding the article 
title not being representative of the study was also associated with sponsorship 
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(p=0.012); industry-supported trials more often received this comment (8.1%) 
than non-industry (5.0%) and industry-sponsored trials (1.5%).
In Table 3, the mean percentage of comments on a manuscript is compared by 
the direction of trial results. For most types of comments, there was no significant 
difference according to whether manuscripts reported positive or negative results. 
However, the percentage of comments regarding inappropriate conclusions was 
higher for articles with negative trial results (29.3%) than for articles with positive 
results (18.9%, p=0.010). 
Table 4 shows the mean percentage of comments on a manuscript according to 
the decision about acceptance. The percentage of comments about the research 
question not being clinically relevant was higher among rejected manuscripts 
(7.8%) than accepted manuscripts (1.6%, p=0.002). Rejected manuscripts were 
more likely to receive comments regarding lack of novelty (8.3%) than accepted 
manuscripts (2.6%, p=0.008). In addition, the percentage of comments about poor 
experimental design was higher for rejected manuscripts (68.6%) than for those 
that were accepted (50.5%, p<0.001). Reviewers more often reported that a study 
was insufficiently related to the literature among manuscripts that were accepted 
(18.6%) compared to those that were rejected (10.5%, p=0.041).
In Table 5, the number of different types of comments per manuscript is shown, 
which was adjusted for the number of reviewers per manuscript. Overall, reviewers 
reported a mean number of 7.8 different types of comments per manuscript (range, 
1 to 15 types of comments). The number of types of comments per manuscript 
was not associated with the direction of results or the decision about acceptance 
of manuscripts. There was a significant relation between sponsorship and the 
number of different types of comments per manuscript (p=0.035); non-industry 
trials on average received more types of comments per manuscript (8.2) than 
industry-sponsored trials (7.2).
Discussion
This is the first study in which real life peer review comments made on submitted 
manuscripts were compared according to sponsorship, direction of results, and 
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Table 3. Distribution of reviewer comments -  by direction of trial results
Mean percentage of comments 
on a manuscript (95% CI)*
Type of comment
Negative 
results (N=96)
Positive results 
(N=150)
P-value
Importance
1. Research question not clinically relevant 4.3 (1.1-7.5) 5.9 (3.1-8.7) 0.469
Originality
2. Lack of novelty 3.5 (0.6-6.3) 7.4 (4.4-10.4) 0.066
Background and rationale
3. Incorrect background information 20.3 (14.9-25.8) 18.9 (14.5-23.3) 0.670
4. Poor justification for conducting study 4.2 (1.3-7.2) 3.0 (1.2-4.9) 0.497
Methods
5. Poor experimental design 64.9 (56.9-73.0) 60.0 (54.5-65.5) 0.285
6. Methods inadequately reported 55.4 (48.2-62.6) 56.3 (50.7-61.9) 0.844
7. Statistical analysis methods inappropriate 23.7 (17.3-30.1) 20.5 (15.7-25.3) 0.453
Results
8. Study outcome data incomplete 61.4 (53.5-69.2) 66.4 (61.0-71.8) 0.266
9. Flow of participants through study unclear 5.5 (2.3-8.8) 7.4 (4.5-10.3) 0.411
Discussion and conclusion
10. Meaning results inadequately discussed 47.8 (40.0-55.7) 48.5 (42.1-54.8) 0.889
11. Study insufficiently related to literature 12.6 (7.7-17.5) 13.7 (9.7-17.7) 0.748
12. Limitations not sufficiently discussed 14.4 (9.4-19.3) 18.4 (14.3-22.4) 0.203
13. Conclusions inappropriate 29.3 (22.6-36.0) 18.9 (14.0-23.9) 0.010
Abstract
14. Abstract does not correctly reflect paper 16.4 (11.4-21.4) 15.5 (11.8-19.2) 0.790
15. Discrepancies between abstract and main text 1.9 (0.1-3.6) 0.8 (0.0-1.8) 0.320
References
16. References missing/irrelevant references used 14.9 (9.8-20.0) 8.6 (5.8-11.5) 0.079
17. Errors in reference citation 2.3 (0.3-4.3) 2.8 (1.1-4.4) 0.731
Presentation
18. Title not representative of study 6.7 (2.5-10.9) 3.6 (1.7-5.5) 0.191
19. Poor writing 38.4 (31.4-45.4) 38.4 (32.5-44.3) 0.997
20. Inaccurate tables or figures 35.1 (28.6-41.6) 41.4 (36.1-46.7) 0.156
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21. Ethics committee approval not clear 1.4 (0.0-3.0) 2.2 (0.7-3.7) 0.463
22. Other ethical issues related to study 2.0 (0.1-3.9) 3.8 (1.4-6.2) 0.267
Trial registration, protocol, CONSORT
23. Registration/protocol/CONSORT missing 1.9 (0.1-3.6) 3.0 (1.3-4.8) 0.352
24. Deviations from registry or protocol 1.8 (0.0-4.0) 1.4 (0.2-2.7) 0.758
Conflicts of interest (COI)
25. Bias by author COIs/contribution funder 
unclear
1.9 (0.1-3.6) 3.3 (1.5-5.1) 0.254
26. Systematic bias or spin in favour of sponsor 0.0 (0.0-1.1) 1.0 (0.0-2.0) 0.120
* The mean percentage of comments on a manuscript is controlled for the journal to which a 
manuscript was submitted. N=number of submitted manuscripts; CI=confidence interval.
decision about acceptance. Previous studies have been limited to experiments 
with fictitious manuscripts.[11, 12] The most frequently reported comments by 
reviewers included poor experimental design, inadequately reported methods, 
incomplete study outcome data, inadequate discussion of the meaning of results, 
poor writing, and inaccurate tables or figures, which is in line with findings of 
previous studies.[7, 9, 10, 18] Reviewers rarely reported on ethics, trial registration, 
or conflicts of interest, as was expected from prior research.[10, 19, 20]
Submitted manuscripts on industry-sponsored trials more often received 
comments regarding a lack of novelty compared to industry-supported and non-
industry trials. However, we found no significant difference according to sponsor 
type for comments on the clinical relevance of research questions. It has been 
argued in literature that studies by pharmaceutical companies may be less 
innovative than non-industry studies. Drug companies may more often focus 
on late-stage drug development and producing variations of drugs already on 
the market, while academia may be more likely to perform creative, early-stage 
clinical research.[22, 23] Interestingly, industry-supported trials were least often 
criticized by reviewers for lack of novelty. This may suggest that collaboration 
between academia and the pharmaceutical industry could potentially lead to 
more innovative clinical studies.  
Non-industry trials were more likely to receive comments regarding poor 
experimental design and inappropriate statistical analysis methods than 
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Table 4. Distribution of reviewer comments - by  decision about acceptance
Mean percentage of comments on a 
manuscript (95% CI)*
Type of comment
Rejected 
(N=150)
Accepted 
(N=96)
P-value
Importance
1. Research question not clinically relevant 7.8 (4.5-11.1) 1.6 (0.0-3.5) 0.002
Originality
2. Lack of novelty 8.3 (4.9-11.6) 2.6 (0.6-4.7) 0.008
Background and rationale
3. Incorrect background information 20.3 (15.8-24.8) 18.0 (12.7-23.3) 0.491
4. Poor justification for conducting study 2.4 (0.8-4.1) 4.9 (1.9-7.9) 0.168
Methods
5. Poor experimental design 68.6 (63.3-73.9) 50.5 (42.8-58.2) <0.001
6. Methods inadequately reported 57.7 (51.8-63.6) 52.7 (45.5-59.9) 0.306
7. Statistical analysis methods inappropriate 21.8 (16.7-27.0) 20.8 (15.1-26.4) 0.793
Results
8. Study outcome data incomplete 62.4 (56.4-68.5) 68.2 (61.3-75.1) 0.178
9. Flow of participants through study unclear 8.2 (4.8-11.5) 4.8 (2.3-7.2) 0.110
Discussion and conclusion
10. Meaning results inadequately discussed 45.5 (39.1-51.9) 53.1 (45.6-60.6) 0.092
11. Study insufficiently related to literature 10.5 (7.1-14.0) 18.6 (13.0-24.2) 0.041
12. Limitations not sufficiently discussed 16.0 (12.3-19.8) 18.3 (12.8-23.8) 0.454
13. Conclusions inappropriate 23.1 (17.9-28.3) 21.8 (15.4-28.2) 0.755
Abstract
14. Abstract does not correctly reflect paper 15.7 (12.0-19.4) 16.1 (11.2-21.1) 0.891
15. Discrepancies between abstract and main text 1.5 (0.2-2.8) 0.8 (0.0-1.9) 0.419
References
16. References missing/irrelevant references used 11.6 (8.0-15.2) 11.6 (6.6-16.7) 0.990
17. Errors in reference citation 2.7 (1.0-4.4) 2.5 (0.6-4.3) 0.843
Presentation
18. Title not representative of study 6.2 (3.1-9.2) 2.9 (0.8-4.9) 0.080
19. Poor writing 37.5 (31.6-43.3) 40.0 (32.7-47.4) 0.555
20. Inaccurate tables or figures 36.7 (31.5-41.9) 43.3 (36.3-50.2) 0.121
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21. Ethics committee approval not clear 1.8 (0.4-3.2) 2.1 (0.3-3.8) 0.839
22. Other ethical issues related to study 4.1 (1.5-6.7) 1.6 (0.1-3.2) 0.115
Trial registration, protocol, CONSORT
23. Registration/protocol/CONSORT missing 3.0 (1.2-4.9) 2.0 (0.3-3.8) 0.435
24. Deviations from registry or protocol 2.2 (0.6-3.9) 0.8 (0.0-2.2) 0.217
Conflicts of interest (COI)
25. Bias by author COIs/contribution funder 
unclear
3.7 (1.7-5.6) 1.6 (0.1-3.2) 0.116
26. Systematic bias or spin in favour of sponsor 1.1 (0.1-2.1) 0.0 (0.0-0.9) 0.054
* The mean percentage of comments on a manuscript is controlled for the journal to which a 
manuscript was submitted. N=number of submitted manuscripts; CI=confidence interval.
industry-supported and industry-sponsored trials. In addition, non-industry trials 
received significantly more different types of comments per manuscript than 
industry-sponsored trials. Prior research based on published articles showed that 
the methodological quality of trials funded by pharmaceutical companies was 
equal to or tended to be higher than that of non-industry trials.[24-27] Previously, 
we studied the shortcomings of protocols of drug trials that were submitted for 
approval to research ethics committees (RECs).[28] Based on the comments raised 
during REC review, we found that non-industry trials more often had shortcomings 
regarding methodology and statistical analyses than industry-sponsored trials 
[28], which is in line with findings of the current study.
Manuscripts with negative results were more likely to receive comments 
regarding overinterpretation or inappropriate conclusions in relation to results 
than manuscripts with positive results. The number of types of comments 
per manuscript was not associated with the direction of results. Evidence of 
inconsistencies between results and the interpretation of findings has previously 
been shown for published articles, especially among those with negative results.
[29, 30] Authors may shape the impression of results in articles, that is, to add 
‘spin’ to reports. Spin includes the use of specific reporting strategies to highlight 
that the experimental treatment is effective, despite non-significant results for the 
primary outcome, or to distract readers from non-significant results. This distorts 
the interpretation of results and misleads readers.[30, 31] 
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Rejected manuscripts had more often received comments on the research 
question not being clinically relevant, lack of novelty, and poor experimental 
design than accepted papers. The number of types of comments per manuscript 
was not associated with decision about acceptance though. Although we found 
significant differences between comments for articles that were eventually rejected 
or accepted, there are many reasons why papers can get rejected beyond what 
is in reviewer reports for the initial submitted version of manuscripts. Moreover, 
editorial processes and the amount of weight put on reviewer comments when 
making publication decisions can be very variable across journals. Papers that 
reviewers are positive about may be rejected, while others are published despite 
of negative reviewer comments. As manuscript review by journals is a complicated 
and multistage process, it is difficult to determine the exact influence of reviewer 
comments in editorial decision making.
This study is strengthened by the inclusion of manuscripts submitted to a general 
medical journal and specialty journals across different medical specialties. The 
studies by Bordage and Turcotte et al. were limited to articles on research in 
medical education or anaesthesia, which reduced the generalizability of their 
findings.[9, 10] Hopewell et al. included open peer review journals where reviewer 
Table 5. Number of different types of comments per article
Mean number of types of 
comments (95% CI)*
P-value
Sponsor type 0.035
Non-industry 8.2 (7.6-8.8)a
Industry-supported 8.0 (7.4-8.6)
Industry-sponsored 7.2 (6.6-7.8)a
Trial results 0.794
Positive 7.8 (7.3-8.2)
Negative 7.9 (7.3-8.4)
Decision about acceptance 0.145
Rejected 8.0 (7.6-8.5)
Accepted 7.5 (6.9-8.0)
* The mean number of types of comments per manuscript is controlled for the number of reviewers 
per manuscript. a The p-value for the mean difference between non-industry and industry-sponsored 
trials is <0.05. CI=confidence interval.
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comments are included alongside published articles. Reviewers may more often 
provide rather uncritical comments when reviewing for such journals, as they may 
fear reprisals for criticizing other researchers’ work openly.[7, 32] In this study, we 
assessed the comprehensiveness of the classification checklist in two training 
sessions. Reviewer comments for 20% of the included manuscripts were scored 
by two raters and the level of inter-rater agreement was good. In previous studies, 
the classification of reviewer comments was completely conducted by a single 
author.[9, 10]  
This study has some limitations. We focused on peer review comments for the 
first submitted version of articles. Some journals may send revised versions to 
new reviewers or back to the same reviewers. By focussing on reviews of initial 
versions, new comments raised during reviews of revisions may have been missed. 
However, initial reviewer reports often contain the most extensive comments 
and provide adequate information to compare reviewer comments according to 
sponsorship, direction of results, and decision about acceptance. We have not 
assessed whether shortcomings that were detected by reviewers were corrected 
in revised manuscripts. Hopewell et al. found that most authors complied with 
requests by reviewers in their revised version [7], but this was beyond the scope of 
this study. In addition, we included a sample of manuscripts describing drug RCTs 
and our results may therefore not be generalizable to other study designs or RCTs 
with other interventions.
Although peer review is generally assumed to raise the quality of submitted papers 
and to provide a mechanism for rational and fair editorial decision making [33], 
reviewer comments may not automatically provide an objective reflection of the 
quality of articles. While the evidence on the effectiveness of peer review is limited 
[2, 6, 33], there is considerable evidence on its defects.[2, 34] In studies where major 
errors were inserted into papers that were subsequently sent to reviewers, none of 
the reviewers spotted all of the errors.[4, 35] In addition, it has been suggested that 
peer review is a subjective and, therefore, inconsistent process.[34] Agreement 
between reviewers in their recommendations for manuscripts may be low.[36] 
Nevertheless, peer review is seen by researchers as important and essential for 
scientific communication and as the best alternative currently available.[34, 37]
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In conclusion, peer reviewers identified less shortcomings regarding design 
and statistical analyses in industry-related trials, but commented more often 
on a lack of novelty in industry-sponsored trials. Negative trial results did not 
significantly influence the nature of comments other than appropriateness of the 
conclusion. Manuscript acceptance was primarily related to the research question 
and methodological robustness of the study. As some of the manuscripts’ 
shortcomings represent fundamental methodological weaknesses, better training 
on trial design and analysis may be appropriate, especially for non-industry trials. 
Other errors are more just omissions, including frequently reported shortcomings 
such as inadequate reporting of methods and incomplete reporting of study 
outcome data. These fixable errors can be avoided if authors pay more attention 
to reporting quality in manuscripts.
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Supplemental Table 1. Checklist for classification of peer review comments 
Category Type of comment
Importance
1. Research question and results of limited clinical relevance/narrow 
interest
Originality
2. Lack of novelty; paper does not add much to what is already in the 
published literature 
Background 
and rationale
3. Incorrect/missing background information in introduction
4. Poor justification for conducting the study; insufficient problem 
statement/rationale provided
Methods 
5. Poor experimental design; methodology/study population/data 
collection methods flawed or questionable
6. Methods inadequately reported; trial design, participants, interventions, 
outcome measures used, sample size calculation, randomisation, or 
blinding inaccurately described 
7. Statistical analysis methods inappropriate or inadequately reported 
Results 
8. Results not answering study question, study outcome data incomplete, 
results inaccurately presented
9. Flow of participants through the study unclear; no explanations provided 
for non-randomized/excluded subjects or drop-outs
Discussion 
and 
conclusion 
10. Meaning of study results inadequately discussed; potential explanations 
and implications insufficiently addressed in discussion
11. Study insufficiently related to prior work in the literature; not discussed 
how study results support or disagree with previous research
12. Limitations/shortcomings of the study not acknowledged or not 
sufficiently discussed how they might affect the study results and their 
interpretation
13. Conclusions inappropriate in relation to study design or results, or 
overinterpretation of results
Abstract
14. Abstract does not correctly reflect the paper; information in abstract 
incomplete/inaccurate
15. Discrepancies between data reported in abstract and main text of the 
paper
References
16. References missing in article, or outdated/irrelevant references used 
17. Errors in reference citation; references not appropriate for statements 
they are meant to support
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Presentation
18. Title not representative of the study 
19. Poor writing; typos, unclear language, incorrect terminology, text difficult 
to follow, wordiness, incorrect use of sections in paper
20. Inaccurate/absent/incomplete tables or figures, discrepancies between 
tables, or discrepancies between main text and tables
Ethics
21. Not clear which research ethics committee provided approval for the 
study
22. Informed consent procedures inadequately reported, or other ethical 
issues related to the study
Trial 
registration, 
protocol, 
CONSORT 
23. Trial registration absent/incomplete or registration number missing, 
study protocol not published/provided by authors, or CONSORT 
statement/diagram missing
24. Deviations from the trial registry or protocol; not adequately explained 
why these deviations occurred
Conflicts of 
interest 
25. Potential bias introduced by author conflicts of interest, or funder’s 
contribution to the study unclear
26. Systematic bias or spin in the interpretation of results in favour of the 
study sponsor
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Supplemental Table 2. Inter-rater agreement for final classification checklist
Type of comment
Percentage of 
agreement
1. Research question of limited clinical relevance 93.1
2. Lack of novelty 94.4
3. Incorrect/missing background information 93.1
4. Poor justification/rationale for conducting study 97.2
5. Poor experimental design 86.1
6. Methods inadequately reported 84.7
7. Statistical analysis methods inappropriate 81.9
8. Study outcome data incomplete 83.3
9. Flow of participants through study unclear 94.4
10. Meaning results inadequately discussed 77.8
11. Study insufficiently related to literature 91.7
12. Limitations not sufficiently discussed 76.4
13. Conclusions inappropriate/overinterpretation 84.7
14. Abstract does not correctly reflect paper 91.7
15. Discrepancies between abstract and main text 98.6
16. References missing/irrelevant references used 95.8
17. Errors in reference citation 95.8
18. Title not representative of study 97.2
19. Poor writing 91.7
20. Inaccurate tables or figures 88.9
21. Ethics committee approval not clear 98.6
22. Other ethical issues related to study 98.6
23. Registration/protocol/CONSORT missing 97.2
24. Deviations from registry or protocol 100.0
25. Bias by author COIs/contribution funder unclear 100.0
26. Systematic bias or spin in favor of sponsor 98.6
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Introduction
Over the last years, the quality of clinical drug research has frequently 
been criticized. In particular, it has been suggested that involvement of the 
pharmaceutical industry adversely affects the quality of clinical trials, which could 
lead to distorted information on drug treatments that is misleading for doctors and 
patients.[1-4] The benefits of interventions may be overestimated, while harmful 
effects are underestimated.[5] As a consequence, patients may be put at risk and 
healthcare resources are wasted. Although the quality of clinical research and 
the influence of the pharmaceutical industry on drug trials are of great interest, 
previous research has often focused on either industry-sponsored or non-profit 
trials, and the number of systematic comparisons between both types of studies is 
limited. This thesis aimed to further investigate the influence of the funding source 
in clinical drug research by conducting a series of studies that focused on different 
aspects of trial quality. This chapter provides a summary of the findings presented 
in this thesis, followed by a general discussion.
Summary
Prior to the recruitment of participants, study protocols are evaluated by research 
ethics committees (RECs) to assess whether all scientific, ethical, and legal 
requirements for conducting research with human subjects are met. In Chapter 2 
of this thesis, we assessed the shortcomings of protocols that were submitted to 
RECs for approval in 2010-2011. Three Dutch RECs provided access to submitted 
protocols and their correspondence with investigators. Based on comments raised 
during REC review, we identified recurring shortcomings in protocols of drug trials 
and assessed whether these were more common among industry-sponsored or 
non-industry trials. REC comments were extracted from decision letters sent to 
investigators and were classified using a predefined checklist. Most protocols 
received comments regarding participant information sheets and consent forms, 
methodology and statistical analyses, and supporting documentation including 
trial agreements and certificates of insurance. This corresponds to findings of 
previous studies on issues raised by RECs.[6-9] Non-industry trials more often 
received comments related to methodology and statistical analyses and the 
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selection of participants than industry-sponsored trials. In contrast, non-industry 
trials less often received comments on supporting documentation than industry-
sponsored trials. 
Several studies on publication bias have been undertaken, in particular on the 
association between sponsorship and favorable trial outcomes.[10-12] However, 
no standardized methodology for the classification of results and sponsorship 
based on the information in published articles has been described. Dissimilarities 
in this assessment impede the ability to compare results of studies on publication 
bias. In Chapter 3, we provided recommendations for a uniform assessment of 
publication bias related to funding source. As part of our study into publication 
bias (Chapter 4), we reviewed manuscripts on randomized controlled trials 
(RCTs) with drugs submitted to eight medical journals, and extracted information 
on results and sponsorship. During the start of this evaluation, we encountered 
several problems related to the classification of results as positive or negative, 
inclusion of post-hoc analyses and follow-up studies of RCTs in the study sample, 
and assessment of the role of the funding source. We composed a comprehensive 
list of recommendations addressing these problems. We proposed to distinguish 
between non-industry, industry-supported, and industry-sponsored trials. The 
reliability and usability of the recommendations were tested through evaluation 
of manuscripts submitted to journals included in our study. The proposed 
recommendations represent a uniform method of classifying trial results and 
sponsorship, which is essential to draw valid conclusions on the role of the funding 
source in publication bias and ensures consistency across future studies. 
Publication bias is generally ascribed to authors and sponsors failing to submit 
studies with negative results, but may also occur after submission to journals.
[13, 14] In Chapter 4, we evaluated whether submitted manuscripts on RCTs with 
drugs were more likely to be accepted if they reported positive results. We included 
manuscripts submitted from January 2010 through April 2012 to one general 
medical journal (BMJ) and seven specialty journals (Annals of the Rheumatic 
Diseases, British Journal of Ophthalmology, Gut, Heart, Thorax, Diabetologia, 
and Journal of Hepatology). Publication status was retrieved from manuscript 
submission systems or provided by journals. Sponsorship and trial results were 
extracted from manuscripts and classified according to the recommendations 
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described in Chapter 3. We found that submitted manuscripts were not more 
likely to be published if they had positive results. This confirms findings of previous 
studies that followed manuscripts submitted to journals.[15-18] The proportion 
of submitted manuscripts with positive results outnumbered those with negative 
results. Both submitted non-industry and industry-sponsored trials were more 
likely to report positive results. This study indicated that for the selected journals, 
there was no tendency to preferably publish manuscripts with positive results, 
suggesting that publication bias may occur mainly prior to submission.
Trial registration has been introduced to increase transparency and accountability 
in the clinical trial process and to address selective publication of results.[19, 20] 
Although registration is now widely implemented, selective outcome reporting 
remains to be prevalent among registered trials.[21] This suggests that registered 
trial information may not be sufficiently considered during manuscript review 
by journals to identify changes to trial characteristics. In Chapter 5, we assessed 
whether journals were more likely to reject manuscripts with differences between 
trial information in registries and that in submitted articles, using the same cohort 
of manuscripts as described in Chapter 4. The extent of differences between 
registered and reported information was compared by sponsor type. For each 
manuscript, we extracted the reported number of participants and the number 
and nature of primary outcomes. In addition, the anticipated sample size and 
primary outcomes in the registry and the timing of registration were reviewed. For 
a substantial proportion of the manuscripts, differences between registries and 
articles were found for the sample size and primary outcome. Industry-sponsored 
trials less often had differences between registered and reported information 
than non-industry or industry-supported trials and were more often prospectively 
registered, that is, before the study start date. We found that differences between 
information in registries and articles and retrospective registration were not 
associated with a decreased chance of acceptance. In several manuscripts, 
primary outcome differences favored publication of statistically significant 
outcomes, which was also found in previous studies.[22, 23] Our study showed 
that differences between registered and reported information were not decisive 
for rejection. Journal editors should assess the consistency between registries and 
articles to address selective reporting. 
148
Chapter 7
At peer-reviewed journals, submitted articles are sent out for external review if 
they are considered to be potentially suitable for publication. During peer review, 
manuscripts are scrutinized by independent experts to assist editors in their 
decision making and to help improve the quality of articles.[24, 25] In Chapter 6, 
we performed a descriptive content analysis of peer review comments made on 
the cohort of manuscripts described in Chapter 4. We investigated the relationship 
between the content of reviewer comments and sponsorship, direction of trial 
results, and the decision about acceptance. Reviewer comments were classified 
using a predefined checklist. The types of comments most frequently reported 
included poor experimental design, inadequately reported methods, incomplete 
study outcome data, inadequate discussion of the meaning of results, poor 
writing, and inaccurate tables or figures, which was in line with findings of 
previous studies.[26-29] This study showed that peer reviewers identified less 
shortcomings regarding design and statistical analyses in industry-related trials, 
but commented more often on a lack of novelty in industry-sponsored trials. 
Negative trial results did not significantly influence the nature of comments other 
than appropriateness of the conclusion. Manuscript acceptance was primarily 
related to the research question and methodological robustness of the study. As 
some of the manuscripts’ shortcomings represent fundamental methodological 
weaknesses, better training on trial design and analysis may be appropriate, 
especially for non-industry trials. Other errors are more just omissions. These 
fixable errors can be avoided if authors pay more attention to reporting quality in 
manuscripts.
General discussion
This thesis focused on the influence of the funding source on the quality of clinical 
drug research. Below, we compare our results to the existing literature on this 
topic and consider the methodological strengths and limitations of our studies. 
We make recommendations for further improvement of the quality of clinical drug 
research and provide suggestions for future studies.
Comparison of findings with previous studies
Every drug trial can be divided into consecutive steps, from the design of the study, 
the actual conduct of the trial, to the publication of results. The quality of a trial 
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can be affected during each of these steps. Several ways have been described in 
which adjustments during the design phase can increase the chance of detecting 
superiority for the experimental treatment.[30-32] However, these choices can 
affect the clinical relevance of study results and the applicability of the trial to the 
population that will actually take the drug, that is, the external validity.[33] Very 
few studies have directly assessed the influence of sponsorship on trial design 
and the external validity of drug trials. In our analysis of peer review comments, 
industry-sponsored trials more often received comments regarding a lack of 
novelty compared to industry-supported and non-industry trials. However, we 
found no differences according to sponsor type for reviewer comments on the 
clinical relevance of the research question and study results. It has been suggested 
in literature that industry-sponsored studies sometimes address less relevant 
issues and examples have been given of clinically non-representative trial designs 
that were allegedly chosen to increase the chance of finding positive results [2], 
but we could not confirm this concern based on comments by peer reviewers. 
Previous studies on the relationship between sponsorship and trial design have 
mainly focused on the comparator treatments used. A number of studies showed 
that industry-sponsored trials more often use placebos or no treatment as control 
groups than non-industry trials [34-37], but others found no differences according 
to sponsorship [38, 39] or even reported that industry-sponsored trials were more 
likely to use active comparators and non-profit trials were more often placebo 
controlled trials.[11] 
During the actual conduct of clinical trials, the risk of systematic bias should 
be minimized, so observed treatment effects can be ascribed to differences in 
treatment and not bias. Several studies have compared the methodological 
quality of trials according to sponsorship. These studies indicated that the 
methodological quality of industry-sponsored trials was equal to that of non-
industry trials [10, 40-42], or tended to be higher for industry-sponsored trials.
[34, 43-46] In our study on shortcomings of protocols of drug trials submitted to 
RECs, we found that non-industry trials more often received comments by RECs 
on methodology and planned statistical analyses than industry-sponsored trials. 
In our analysis of the content of peer review comments, we also found that non-
industry trials were more likely to receive comments regarding poor experimental 
design and inappropriate statistical analysis methods. Moreover, comments 
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regarding methodological issues were in both studies among the errors that were 
most frequently reported. 
The majority of the literature on the influence of sponsorship on clinical drug 
research has focused on publication of results. It has repeatedly been shown that 
published studies that are sponsored by pharmaceutical companies are more 
likely to have outcomes that are favorable to the sponsor than studies with other 
funding sources.[10, 11, 34, 40, 43, 47] Publication bias and outcome reporting bias 
are often mentioned as explanations.[34, 43] However, our study on publication 
bias in editorial decision making showed that both submitted non-industry and 
industry-sponsored drug trials were more likely to report positive results than 
negative results. In addition to selective publication of entire studies, it has also 
been shown that trials are published with other primary outcomes than originally 
described in protocols or trial registries.[21-23, 48, 49] These discrepancies 
favored publication of favorable outcomes in several trials.[22, 23] Differences 
have also been found between registered and published secondary outcomes, 
eligibility criteria, and sample sizes.[49-51] In our analysis of differences between 
information in registries and submitted manuscripts, industry-sponsored trials 
less often had discrepancies between registered and reported primary outcomes 
and sample sizes than non-industry or industry-supported trials. In addition, 
industry-sponsored trials were more often registered before the start of the study, 
which is required according to the ICMJE guidelines.[24] Discrepancies between 
registries and articles have not been compared according to sponsor type in earlier 
studies. In addition to selective publication, authors may shape the impression of 
their results in articles by adding ‘spin’ to reports. This distorts the interpretation 
of results and misleads readers.[52, 53] In our analysis of peer review comments, 
manuscripts with negative results were more likely to receive comments regarding 
overinterpretation or inappropriate conclusions in relation to results than papers 
with positive results. Previous studies also reported inconsistencies between 
results and the interpretation of findings in published papers, especially among 
those with negative results.[52, 54] In our study, reviewers often commented 
on inadequate reporting of methods or study outcome data, but there were 
no differences according to sponsorship regarding inaccurate reporting of 
methods and results or inappropriate conclusions. Research on the influence of 
implementation of the CONSORT statement also showed that, although reporting 
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of several aspects of trial methods had improved in published papers, the overall 
reporting quality still remained below an optimal level.[55] 
Methodological strengths and limitations of this thesis
In this thesis, we used two main study cohorts. The first cohort consisted of 
protocols of drug trials submitted to three RECs affiliated to academic medical 
centers in The Netherlands (Chapter 2). We included 226 protocols and had 
unrestricted access to all trial documents submitted by investigators and to the 
correspondence between RECs and investigators. The second cohort consisted 
of 472 manuscripts reporting the results of drug RCTs that were submitted to 
one general medical journal and seven specialty journals (Chapter 4, 5, and 6). 
These journals provided access to submitted manuscripts, peer review reports, 
and final decisions on publication. Because of this cooperation of RECs and 
journals we had insight into the ethical review process and the editorial decision 
making process, which is not commonly provided to external researchers. The 
retrospective design of our studies overcomes the limitations that prospective 
studies on this topic have. Due to the retrospective design of our REC study, 
included protocols were already reviewed before RECs were asked to participate 
in this study and the behavior of REC members was not influenced by awareness 
of an ongoing investigation. This also applies to our study on publication bias in 
editorial decision making. In prospective studies, the decision-making behavior 
of editors may be influenced by knowledge of an ongoing study [15], introducing 
bias into the selection of manuscripts that are accepted for publication. 
In this thesis, we aimed to study different aspects of trial quality. However, the 
availability of validated instruments to evaluate trial quality is limited. Very few 
studies have described methods to assess external validity [56-58]. There are some 
different tools that have been developed to assess the methodological quality of 
published trials [59], including the Jadad scale [60] and the Cochrane Risk of bias 
tool.[61] However, although these instruments should emphasize on assessment 
of the risk of bias during the conduct of the study, they tend to confuse this with 
evaluation of the adequacy of reporting in published trials.[58, 61, 62] As a result, 
well conducted but badly reported trials will be misclassified.[58] An alternative 
approach is to explicitly assess the quality of the reporting rather than the adequacy 
of the methods. Adherence to the CONSORT statement has been used to assess 
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the quality of reporting. [55, 63, 64] However, assessment of reporting quality also 
has its limitations as biased but well reported trials will receive full credit.[58] 
Because of this lack of appropriate instruments, we developed new checklists to 
evaluate the shortcomings of protocols of drug trials submitted to RECs and to 
analyze the content of peer review comments made on submitted manuscripts on 
drug trials. In addition, we defined criteria for the classification of trial results and 
sponsor type, as no standardized methodology for assessment of outcomes and 
sponsorship has been described. However, these classification checklists were 
applied for the first time in this thesis and have only been validated for use in our 
studies. To prove whether the checklists are acceptable to researchers in general, 
their internal and external validity should be further verified in future studies by 
different researchers and with different cohorts of trials. 
The categorization of REC comments and peer review comments may be 
considered as subjective. Ideally, all comments would have been independently 
classified by two raters and in case of disagreement between raters, a decision 
would have been made by a third researcher. However, the majority of comments 
were classified by one rater in our studies. These studies had an explorative 
character though and categorization of all comments by two raters was not 
feasible due to logistical reasons. It should be noted that the comments that 
are raised by RECs and peer reviewers may not inherently provide an objective 
reflection of the quality of submitted protocols or manuscripts. It has been shown 
that REC review can be variable regarding the decisions made on protocols [65-
67] and that the comments raised may differ by REC even for the same protocol 
with multicenter trials.[67, 68] There is also substantial literature on the defects 
of peer review.[25, 69] It has been suggested that peer review is a subjective 
and, therefore, inconsistent process.[69, 70] However, as described above, the 
availability of alternative instruments to evaluate the quality of clinical trials is 
limited at this moment.
In our study on publication bias in editorial decision making, we included a 
general medical journal and specialty journals across different medical specialties. 
However, these journals are merely a sample of all peer reviewed medical 
journals. The journals that agreed to participate may have chosen to do this based 
on existing editorial policy to publish papers of scientific worth regardless of the 
153
Summary and general discussion
7
direction of results. As both BMJ and 5 of the 7 specialty journals are published 
by the BMJ Group, the results presented in Chapter 4, 5, and 6 may have been 
affected by clustering effects based on publisher policy. 
Future perspectives
Clinical trials are conducted to obtain generalizable information that will improve 
medical knowledge and support clinical decision making by doctors. However, 
the utility of clinical trials is dependent on how they are used. First, trials should 
use optimal study designs. They should ask questions that matter to patients, 
and they should be informed by systematic reviews of previous research.[71] 
Trials should be well powered and use relevant comparators, with prospective 
registration of their design and outcomes, and, if possible, of statistical analysis 
plans. Trial results and raw data should be publicly available. When these 
conditions are met, clinical trials could be the best source of information on how 
to improve health.[72] However, both industry-sponsored and non-industry trials 
should be improved before they meet this prescription for what all clinical trials 
should be.
First, investigators should pay more attention to the methodological quality 
of their study before initiation of a clinical trial, especially investigators of non-
industry trials. Involvement of persons with expertise in biostatistics is of vital 
importance during the preparation of clinical trials. In addition to preventing 
shortcomings related to trial methodology and planned statistical analyses, 
academic institutions and other non-profit organizations should be encouraged 
to work together more closely in the conduct of (multicenter) trials, as premature 
discontinuation of trials due to poor recruitment of participants is common.[73] 
It has been shown that non-industry trials have more problems in recruiting the 
required number of subjects than studies initiated by pharmaceutical companies.
[73, 74]
Secondly, the reporting of trial results should be further improved. Some studies 
indicate that non-industry trials are more likely to be published after completion 
than industry-sponsored trials [11, 75], but both pharmaceutical companies and 
non-profit organizations should strive to achieve higher publication rates. One of 
the measures taken to increase transparency in the trial process and to address 
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selective publication included trial registration. Although trial registration is now 
widely implemented and a recent study demonstrated an inverse association 
between reporting of trial registration and positive outcomes in published trials 
[76], there is also evidence indicating that selective outcome reporting remains to 
be prevalent among adequately registered trials.[21-23] As argued for in the AllTrials 
campaign, more should be done to improve transparency in clinical research.[77] 
According to the campaign, planned trials should be prospectively registered and 
past trials that were not registered should be registered retrospectively now. A 
summary of results should be publicly available in trial registries within one year 
of study completion, and summary results from past trials of drugs currently in 
use should be posted on a registry now. Finally, sponsors who produce full reports 
(clinical study reports (CSRs), or their equivalent in non-commercial studies) 
should make these publicly available.[77] The AllTrials campaign should be 
supported by all sponsors and investigators of clinical trials. Furthermore, authors 
of published trial articles should adhere to the CONSORT statement to enable 
readers to completely understand the conduct of a trial and assess the validity of 
its results.
In addition to sponsors and investigators, RECs and editors of medical journals 
can play an important role in improvement of transparency in clinical research. 
Registration of all clinical trials should be a mandatory requirement for REC 
approval. The Health Research Authority (HRA), responsible for the national 
oversight of RECs in the UK, has already made prospective registration a 
requirement for ethical approval of any trial conducted in the UK.[78] Other 
countries should follow this example. To more effectively confront selective 
publication, all medical journals should refuse to publish unregistered trials. In 
addition, journals should publish trial registration numbers so that editors, peer 
reviewers, and readers have access to information that was registered and pre-
specified as part of the study protocol.[79] During manuscript review, editors 
should access trial registries and inquire about outcomes that were selectively 
reported.
With regard to future research, studies should focus more on external validity 
as many trials, registered or not, completed or not, and published or not, may 
represent wasted effort because the questions they ask and the comparisons and 
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outcomes they choose to study are clinically irrelevant.[72] Clinical irrelevance of 
research questions and study results may be one of the biggest sources of waste 
in clinical trials [72, 80], but this issue is relatively underexposed compared to 
the literature on trial registration and publication. One possibility to evaluate the 
clinical relevance of trials may include the use of independent expert panels that 
are presented with summaries of real-life trials and have to make judgments on 
their relevance. These summaries should include at least the research question, 
study design, condition being studied, interventions used, primary and key 
secondary outcome measures, main eligibility criteria, and anticipated sample 
size. The panel should be blinded for sponsorship, and drug interventions should 
be rephrased to include only the class of drugs tested. A measurement scale 
should be developed to score clinical relevance and make comparisons according 
to sponsorship.
Finally, pharmaceutical companies and academic institutions should more often 
team up to tackle the challenges of drug development and clinical research. These 
collaborations can benefit both parties. Pharmaceutical companies will have 
earlier access to novel scientific discoveries, while academia can receive additional 
research funding in times of decreasing grant support.[81] Academia is often best 
at developing scientific leads and proposing novel ideas, while pharmaceutical 
companies are more effective at translating discoveries into therapeutic use. 
These areas of expertise complement one another and, when brought together in 
industry-academic partnerships, can lead to faster drug development and better 
treatments for patients.[82] Moreover, industry and academia can learn from 
each other’s best practices in the conduct of clinical trials, which will improve 
the overall quality of clinical drug research. Collaborations between industry and 
academia have become more common over the last years. Some examples include 
GlaxoSmithKline with the Immune Disease Institute in Boston, AstraZeneca with 
Columbia University Medical Center, Pfizer with the University of California in San 
Francisco, and Gilead Sciences with Yale School of Medicine in New Haven.[81, 83] 
It is important in these projects to limit the influence of any potential biases by both 
academic and industry researchers. Any conflicts of interest among investigators 
and the role of the funding source in the design, analysis, and reporting of the 
study data should be disclosed in published trial reports.[84, 85] 
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Conclusion
This thesis aimed to investigate the influence of the funding source in clinical 
drug research. Both non-industry and industry-sponsored clinical drug trials have 
important shortcomings that should be addressed by investigators and sponsors. 
Investigators, especially of non-industry studies, should pay more attention to 
the methodological quality of their trials. In addition, the quality of reporting in 
published articles should be improved so readers are able to understand the 
conduct of trials and assess the validity of results. Both pharmaceutical companies 
and non-profit organizations should strive to further improve transparency in 
clinical research. All clinical trials should be registered and their results reported 
to reduce selective publication. RECs and medical journals also play an important 
role in addressing publication bias. Future studies should focus on external validity 
as many trials may ask questions and choose to study comparisons or outcomes 
that are clinically irrelevant. Finally, pharmaceutical companies and academic 
institutions should more often team up to tackle the challenges of clinical drug 
research, as these collaborations can benefit both parties. 
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Introductie
De afgelopen jaren is de kwaliteit van klinisch geneesmiddelenonderzoek 
vaak bekritiseerd. Regelmatig wordt er gesuggereerd dat de betrokkenheid 
van de farmaceutische industrie een nadelige invloed heeft op de kwaliteit 
van klinische studies, wat zou kunnen leiden tot vertekende informatie over 
geneesmiddeleninterventies die misleidend is voor artsen en patiënten. De 
gunstige effecten van geneesmiddelen kunnen overschat worden, terwijl de 
schadelijke effecten onderschat worden. Hierdoor kunnen patiënten blootgesteld 
worden aan risico’s voor hun gezondheid en worden schaarse middelen in de 
gezondheidszorg verspild. Hoewel de kwaliteit van klinisch onderzoek en de 
invloed van de farmaceutische industrie sterk in de belangstelling staan, heeft 
eerder onderzoek zich vaak enkel gefocust op industriegesponsorde trials of 
op non-profit trials. Het aantal systematische vergelijkingen tussen beide typen 
studies is beperkt. Het doel van dit proefschrift was om verder onderzoek te doen 
naar de invloed van de financieringsbron in klinisch geneesmiddelenonderzoek, 
door een aantal studies uit te voeren die gericht waren op verschillende aspecten 
van de kwaliteit van klinische trials. In dit hoofdstuk wordt een samenvatting 
gegeven van de resultaten die gepresenteerd worden in dit proefschrift.
Samenvatting
Voordat proefpersonen gevraagd kunnen worden om deel te nemen aan een 
klinische trial, worden onderzoeksprotocollen geëvalueerd door een medisch 
ethische toetsingscommissie (METC) om te bepalen of aan alle wetenschappelijke, 
ethische, en wettelijke verplichtingen voor het uitvoeren van onderzoek met 
humane proefpersonen wordt voldaan. In Hoofdstuk 2 hebben we onderzoek 
gedaan naar de tekortkomingen van studieprotocollen die in 2010-2011 ter 
goedkeuring waren ingediend bij METC’s. Drie Nederlandse METC’s hebben 
toegang gegeven tot ingediende protocollen en hun correspondentie met 
onderzoekers. Op basis van de commentaren die tijdens de METC beoordeling 
gemaakt zijn, hebben we terugkerende tekortkomingen in protocollen voor 
geneesmiddelenstudies geïdentificeerd en hebben we onderzocht of deze 
vaker voorkwamen bij industriegesponsorde of niet-industrie trials. De METC 
commentaren zijn verzameld uit brieven die gestuurd zijn aan onderzoekers en 
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zijn geclassificeerd met behulp van een vooraf opgestelde checklist. De meeste 
protocollen kregen commentaar van de METC op de schriftelijke informatie voor 
proefpersonen en het toestemmingsformulier, de methodologie en statistische 
analyses, en de aanvullende documenten die ingediend moeten worden, zoals 
studiecontracten en verzekeringscertificaten. Niet-industrie trials kregen vaker 
commentaar op de methodologie en statistische analyses en de selectie van 
proefpersonen dan industriegesponsorde trials. Daarentegen kregen niet-
industrie studies minder vaak commentaar op aanvullende documenten dan 
industriegesponsorde trials. 
Er is de afgelopen jaren veel onderzoek gedaan naar de selectieve publicatie van 
trial uitkomsten (publication bias), voornamelijk met betrekking tot de relatie 
tussen sponsoring en publicatie van gunstige onderzoeksresultaten. Er is echter 
geen standaard methodologie beschreven in de literatuur voor de classificatie van 
trial resultaten en sponsoring op basis van informatie in gepubliceerde artikelen. 
Het gebruik van uiteenlopende methoden voor deze classificatie belemmert 
de mogelijkheid om resultaten van verschillende studies naar publication bias 
te vergelijken. In Hoofdstuk 3 hebben we aanbevelingen gegeven voor een 
gestandaardiseerde evaluatie van publicatie bias in relatie tot de financieringsbron. 
Als onderdeel van onze studie naar publicatie bias (Hoofdstuk 4), hebben we 
artikelen over gerandomiseerde gecontroleerde trials (RCTs) met geneesmiddelen 
die waren ingediend bij acht medische tijdschriften bekeken, en informatie over 
de richting van de resultaten en sponsoring uit deze artikelen gehaald. Tijdens de 
start van deze studie kwamen we verschillende problemen tegen met betrekking 
tot de classificatie van trial resultaten als positief of negatief, de inclusie van post-
hoc analyses en follow-up studies van RCTs in het studiecohort, en het bepalen van 
de rol van de financieringsbron. We hebben een complete lijst met aanbevelingen 
opgesteld om deze problemen te adresseren. We stellen voor onderscheid te 
maken tussen niet-industrie, industrieondersteunde, en industriegesponsorde 
trials. De betrouwbaarheid en bruikbaarheid van de aanbevelingen is getest in de 
artikelen ingediend bij de tijdschriften die deelnamen aan onze publication bias 
studie. Deze aanbevelingen vormen een uniforme methode om studieresultaten 
en sponsoring te classificeren, zodat er valide conclusies getrokken kunnen 
worden over de rol van de financieringsbron bij selectieve publicatie en er meer 
consistentie is in toekomstige studies.
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Over het algemeen wordt publicatie bias toegeschreven aan onderzoekers en 
sponsors die het nalaten om studies met negatieve resultaten in te dienen voor 
publicatie in medische tijdschriften, maar publicatie bias kan ook ontstaan na 
indiening. In Hoofdstuk 4 hebben we onderzocht of ingediende artikelen over 
gerandomiseerde gecontroleerde trials (RCTs) met geneesmiddelen een grotere 
kans hadden om geaccepteerd te worden voor publicatie wanneer ze positieve 
resultaten rapporteerden. We hebben artikelen geïncludeerd die waren ingediend 
tussen januari 2010 en april 2012 bij één algemeen medisch tijdschrift (BMJ) en 
zeven specialistische tijdschriften (Annals of the Rheumatic Diseases, British 
Journal of Ophthalmology, Gut, Heart, Thorax, Diabetologia, en Journal of 
Hepatology). De publicatie status van artikelen werd uit manuscript submissie 
systemen gehaald of werd verstrekt door het tijdschrift. Informatie over sponsoring 
en trial resultaten werd uit artikelen gehaald en geclassificeerd aan de hand van de 
aanbevelingen beschreven in Hoofdstuk 3. We vonden dat ingediende artikelen 
geen grotere kans hadden om gepubliceerd te worden wanneer ze positieve 
resultaten hadden. De proportie van ingediende manuscripten met positieve 
resultaten was hoger dan die met negatieve resultaten. Zowel ingediende niet-
industrie als industriegesponsorde trials rapporteerden vaker positieve resultaten. 
Deze studie wijst erop dat er voor de deelnemende medische tijdschriften geen 
neiging was om bij voorkeur manuscripten met positieve resultaten te publiceren, 
wat kan suggereren dat publicatie bias voornamelijk voorkomt vóór indiening bij 
tijdschriften.
Trial registratie is geïntroduceerd om de transparantie en verantwoording bij 
klinische trials te vergroten en selectieve publicatie van studieresultaten tegen te 
gaan. Hoewel trial registratie tegenwoordig op grote schaal geïmplementeerd is, 
blijft selectieve publicatie ook onder trials die adequaat geregistreerd zijn bestaan. 
Dit suggereert dat er door tijdschriften onvoldoende aandacht wordt geschonken 
aan geregistreerde informatie tijdens de evaluatie van artikelen, om veranderingen 
in trial karakteristieken te kunnen identificeren. In Hoofdstuk 5 hebben we 
onderzocht of tijdschriften vaker artikelen afwezen wanneer er verschillen waren 
tussen studie informatie in het trial register en die in het ingediende artikel, door 
gebruik te maken van hetzelfde cohort van artikelen als beschreven in Hoofdstuk 
4. Het aantal artikelen met verschillen tussen geregistreerde en gerapporteerde 
informatie werd vergeleken per sponsor type. Voor ieder artikel achterhaalden 
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we het gerapporteerde aantal proefpersonen en het aantal en de aard van de 
primaire studie uitkomsten. Daarnaast bekeken we het aantal proefpersonen en 
de primaire uitkomsten in het trial register en het tijdstip waarop de studie was 
geregistreerd. Voor een aanzienlijk deel van de artikelen vonden we verschillen 
tussen trial registers en artikelen met betrekking tot het aantal proefpersonen 
en de primaire uitkomst. Industriegesponsorde trials hadden minder vaak 
verschillen tussen geregistreerde en gerapporteerde informatie dan niet-industrie 
of industrieondersteunde trials en waren vaker prospectief geregistreerd, oftewel 
voor de startdatum van de studie. We vonden dat verschillen tussen informatie in 
registers en artikelen en retrospectieve registratie niet geassocieerd waren met een 
lagere kans op publicatie. In verschillende manuscripten waren discrepanties met 
betrekking tot de primaire uitkomst in het voordeel van publicatie van statistisch 
significante resultaten. Deze studie laat zien dat verschillen tussen geregistreerde 
en gerapporteerde informatie niet doorslaggevend waren voor afwijzing door 
tijdschriften. Redacteuren van medische tijdschriften zouden de consistentie 
tussen registers en ingediende artikelen moeten bekijken om selectieve publicatie 
te bestrijden. 
Bij tijdschriften die gebruik maken van peer review, worden ingediende artikelen 
naar externe referenten gestuurd als ze beschouwd worden als artikelen die in 
potentie gepubliceerd kunnen worden. Tijdens peer review worden artikelen kritisch 
beoordeeld door onafhankelijke experts om redacteuren te ondersteunen in het 
maken van beslissingen en de kwaliteit van artikelen te verbeteren. In Hoofdstuk 
6 hebben we peer review commentaren geanalyseerd die waren gemaakt voor 
het cohort van artikelen beschreven in Hoofdstuk 4. We hebben de relatie tussen 
de inhoud van de commentaren en sponsoring, de richting van trial resultaten, 
en de beslissing over publicatie onderzocht. De peer review commentaren zijn 
geclassificeerd met een vooraf opgestelde checklist. Het type commentaren dat 
het meest frequent werd gerapporteerd bestond uit gebrekkige experimentele 
opzet, inadequate rapportage van methoden, incomplete studiedata, inadequate 
discussie van de betekenis van resultaten, slecht geschreven artikelen, en 
inaccurate tabellen en figuren. Deze studie laat zien dat referenten minder 
tekortkomingen vonden met betrekking tot design en statistische analyses bij 
industrie-gerelateerde trials, maar vaker commentaar hadden op een gebrek 
aan innovatie bij industrie-gesponsorde trials. Negatieve studieresultaten waren 
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niet significant van invloed op de aard van de commentaren, met uitzondering 
van de juistheid van de conclusie. Afwijzing van manuscripten was voornamelijk 
gerelateerd aan de onderzoeksvraag en de methodologische robuustheid van 
de studie. Aangezien sommige tekortkomingen in manuscripten fundamentele 
methodologische zwakheden vormen, zou betere training op het gebied van trial 
design en analyse gepast zijn, in het bijzonder voor niet-industrie studies. Andere 
fouten ontstaan meer uit nalatigheid. Deze herstelbare fouten kunnen worden 
voorkomen als onderzoekers meer aandacht besteden aan de kwaliteit van de 
rapportage in manuscripten.  
Conclusie
Het doel van dit proefschrift was om de invloed van de financieringsbron in 
klinisch geneesmiddelonderzoek verder te bestuderen. Zowel niet-industrie als 
industriegesponsorde klinische geneesmiddelenstudies hebben belangrijke 
tekortkomingen die moeten worden aangepakt door onderzoekers en sponsors. 
Onderzoekers, in het bijzonder van niet-industrie studies, zouden meer aandacht 
moeten besteden aan de methodologische kwaliteit van hun trials. Daarnaast 
moet de kwaliteit van de rapportage in gepubliceerde artikelen worden verbeterd, 
zodat lezers in staat zijn om de uitvoering van trials te begrijpen en de validiteit 
van resultaten te kunnen bepalen. Zowel farmaceutische bedrijven als non-profit 
organisaties zouden er naar moeten streven om de transparantie in klinisch 
geneesmiddelenonderzoek verder te vergroten. Alle klinische trials zouden 
moeten worden geregistreerd en hun resultaten gerapporteerd om selectieve 
publicatie terug te dringen. Medisch ethische toetsingscommissies en medische 
tijdschriften spelen ook een belangrijke rol in het bestrijden van publicatie bias. 
Toekomstig onderzoek zou gericht moeten zijn op de externe validiteit van 
geneesmiddelenstudies omdat veel trials mogelijk vragen stellen en er voor 
kiezen om vergelijkingen of uitkomsten te bestuderen die klinisch irrelevant zijn. 
Tenslotte zouden farmaceutische bedrijven en academische centra meer samen 
op moeten trekken om de uitdagingen van klinisch geneesmiddelenonderzoek 
aan te pakken, omdat deze samenwerkingen beide partijen ten goede kunnen 
komen.
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List of abbreviations
ANZCTR Australian New Zealand clinical trials registry
BMJ British medical journal
CI Confidence interval
CONSORT Consolidated standards of reporting trials
CSR Clinical study report
EFPIA European federation of pharmaceutical industries and 
 associations
EMA European medicines agency
EU-CTR EU clinical trials register
EudraCT European Union drug regulating authorities clinical trials
FDA Food and drug administration
FDAAA Food and drug administration amendments act
FDAMA Food and drug administration modernization act
GCP Good clinical practice
GSK GlaxoSmithKline
HRA Health research authority
ICH International conference on harmonisation of technical 
 requirements for registration of pharmaceuticals for human use
ICMJE International committee of medical journal editors
ICTRP International clinical trials registry platform
IF Journal impact factor
IQR Interquartile range
IFPMA International federation of pharmaceutical manufacturers and
 associations
ISRCTN International standard randomized controlled trial number
JPMA Japan pharmaceutical manufacturers association
METC Medisch ethische toetsingscommissie
N Sample size
NIH National institutes of health
NTR Netherlands trial register
OR Odds ratio
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PhRMA Pharmaceutical research and manufacturers of America
RCT Randomized controlled trial
REC Research ethics committee
RR Relative risk
WHO World health organization
WMA World medical association
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Zoals voor alle promovendi geldt, ben ik een groot aantal mensen dank 
verschuldigd voor de samenwerking en steun tijdens mijn promotieonderzoek. 
Op uiteenlopende manieren hebben jullie bijgedragen aan de totstandkoming 
van dit proefschrift. Zonder jullie hulp had ik dit project niet tot een goed einde 
kunnen brengen! 
Professor H.J. Out, beste Henk Jan, je bent vanaf het begin als mijn promotor 
betrokken geweest bij het onderzoek. Tijdens de ruim vier jaar die dit project in 
beslag heeft genomen heb ik altijd veel vrijheid gekregen in de invulling van het 
onderzoek, wat ik als heel erg prettig heb ervaren. Op welk moment van de dag 
ik ook mailde, en of je nu in Nederland of in de VS was, ik kreeg altijd meteen 
een reactie. Hoewel ik veel vrijheid had om mijn onderzoek uit te voeren stelde je 
wanneer het nodig was ook deadlines om de druk een beetje op te voeren en te 
zorgen dat ik niet eindeloos aan een artikel bleef sleutelen. Bedankt voor de fijne 
samenwerking en misschien komen we elkaar in de toekomst wel weer tegen!
 
Professor G.A. Rongen, beste Gerard, in de loop van mijn promotietraject ben 
jij meer betrokken geraakt bij mijn onderzoek en ben je mijn tweede promotor 
geworden. Ik ben blij dat je hiertoe bereid was. Jouw jarenlange ervaring met 
klinische studies was heel waardevol en ik vond het heel prettig om met je samen 
te werken. Ondanks je drukke werkzaamheden kon ik altijd op een snelle en 
uitgebreide reactie rekenen wanneer ik je een manuscript toestuurde. Jij keek 
met een frisse blik naar mijn artikelen, wat altijd nuttig commentaar opleverde. 
Bedankt daarvoor!
De manuscriptscommissie bestaande uit professor E. van Leeuwen, professor 
J. Drenth en professor A. de Boer wil ik graag bedanken voor hun kritische 
beschouwing en goedkeuring van dit proefschrift.
Mijn promotieproject maakte deel uit van de bijzondere leeropdracht die is 
ingesteld door de Dr. Saal van Zwanenberg Stichting. Het onderzoek is gefinancierd 
middels een unrestricted educational grant van MSD Nederland, waarvoor dank.
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De eerste helft van mijn promotieonderzoek heb ik doorgebracht in de prekliniek 
bij de afdeling Farmacologie-Toxicologie. Ik denk met veel plezier terug aan de 
tijd op deze afdeling. Huidige en voormalige collega’s van de prekliniek, bedankt 
voor de gezellige koffiepauzes, lunches, borrels, en afdelingsuitjes. Dank ook voor 
de input tijdens de werkbesprekingen. Professor F.G.M. Russel, beste Frans, je was 
als afdelingshoofd van Farmacologie-Toxicologie weliswaar niet direct inhoudelijk 
betrokken bij mijn onderzoek, maar bedankt voor de steun die je achter de 
schermen gegeven hebt.
Halverwege mijn promotieonderzoek ben ik vanuit de prekliniek verhuisd naar 
het Clinical Research Centre Nijmegen (CRCN). Dr. D. van Duren, beste Dyonne, 
bedankt voor de mogelijkheid om mijn onderzoek bij het CRCN voort te zetten. Ik 
heb me altijd welkom gevoeld op de afdeling en veel kunnen leren over alles wat 
er komt kijken bij het uitvoeren van klinische trials. Het CRCN kan trots zijn op alles 
wat er de afgelopen jaren bereikt is, en ik hoop dat de afdeling blijft bijdragen aan 
de verdere verbetering van de kwaliteit van het klinische onderzoek binnen het 
Radboudumc!
 
Graag wil ik ook mijn andere dagelijkse collega’s van het CRCN benoemen. Beste 
Adrianne, Angelie, Anja, Christel, Evertine, Fenna, Hettie, Inge, Jackie, Karin, 
Luuk, Mariëlle, Marjo, Michel, Mike, Mirjam, Robert, Samantha en Simone, hoewel 
ik als enige binnen het CRCN met mijn eigen onderzoek bezig was, heb ik veel 
opgestoken van jullie kennis en ervaring op het gebied van klinisch onderzoek. Ik 
waardeer jullie betrokkenheid en belangstelling in de afgelopen jaren voor zowel 
dingen binnen als buiten het werk. Jullie zijn een fijne groep collega’s om deel van 
uit te maken! 
 
Professor A.J.P.M. Overbeke, beste John, jouw expertise op het gebied van medisch 
wetenschappelijk publiceren was zeer belangrijk bij de totstandkoming van dit 
proefschrift. Als voormalig hoofdredacteur van het Nederlands Tijdschrift voor 
Geneeskunde heb je jarenlange ervaring en een groot netwerk binnen de wereld 
van de medische tijdschriften. Bedankt voor jouw input bij een groot deel van de 
artikelen in dit proefschrift!
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Beste Joanna, bedankt voor je hulp bij de statistische analyses van de verzamelde 
data. Meestal voldeden recht toe recht aan analyses niet, maar jij vond altijd 
een oplossing om toch een goede analyse uit te voeren. Ook was je altijd bereid 
om mijn manuscripten voor submissie nog eens kritisch te bekijken. Uit onze 
samenwerking zijn een tweetal gezamenlijke publicaties voortgekomen. Veel 
dank hiervoor!
 
De studies beschreven in dit proefschrift hadden niet uitgevoerd kunnen 
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vermogen. Ik ben heel blij dat je me altijd steunt en ik begin de waarheid van jouw 
vaste opmerkingen ‘het is zoals het is’ en ‘het komt wel goed’ in te zien. Vanaf nu 
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